US20140328776A1 - Film forming personal care compositions and methods - Google Patents
Film forming personal care compositions and methods Download PDFInfo
- Publication number
- US20140328776A1 US20140328776A1 US14/332,391 US201414332391A US2014328776A1 US 20140328776 A1 US20140328776 A1 US 20140328776A1 US 201414332391 A US201414332391 A US 201414332391A US 2014328776 A1 US2014328776 A1 US 2014328776A1
- Authority
- US
- United States
- Prior art keywords
- group
- siloxane
- film
- solvent
- pva
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 122
- 238000000034 method Methods 0.000 title abstract description 32
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229920002554 vinyl polymer Polymers 0.000 claims abstract description 22
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims abstract description 20
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims abstract 2
- 239000002904 solvent Substances 0.000 abstract description 46
- 239000004599 antimicrobial Substances 0.000 abstract description 22
- 230000000845 anti-microbial effect Effects 0.000 abstract description 19
- 239000000049 pigment Substances 0.000 abstract description 19
- 239000000565 sealant Substances 0.000 abstract description 12
- 229940030225 antihemorrhagics Drugs 0.000 abstract description 9
- 239000002537 cosmetic Substances 0.000 abstract description 8
- 239000002874 hemostatic agent Substances 0.000 abstract description 8
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 7
- 239000003193 general anesthetic agent Substances 0.000 abstract description 7
- 239000003973 paint Substances 0.000 abstract description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 6
- CQVWXNBVRLKXPE-UHFFFAOYSA-N 2-octyl cyanoacrylate Chemical compound CCCCCCC(C)OC(=O)C(=C)C#N CQVWXNBVRLKXPE-UHFFFAOYSA-N 0.000 abstract description 5
- 238000001704 evaporation Methods 0.000 abstract description 5
- 230000008020 evaporation Effects 0.000 abstract description 5
- 230000002829 reductive effect Effects 0.000 abstract description 4
- 231100000241 scar Toxicity 0.000 abstract description 3
- 239000007921 spray Substances 0.000 abstract description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 58
- -1 alkyl acetate Chemical compound 0.000 description 57
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 54
- 210000003491 skin Anatomy 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- 235000010215 titanium dioxide Nutrition 0.000 description 28
- 150000001241 acetals Chemical class 0.000 description 27
- 239000004408 titanium dioxide Substances 0.000 description 27
- 125000000217 alkyl group Chemical group 0.000 description 22
- 235000019441 ethanol Nutrition 0.000 description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 17
- 239000002245 particle Substances 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 16
- 125000006353 oxyethylene group Chemical group 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 239000002105 nanoparticle Substances 0.000 description 13
- 229910052708 sodium Inorganic materials 0.000 description 13
- 229940083542 sodium Drugs 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 12
- 239000004205 dimethyl polysiloxane Substances 0.000 description 12
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 12
- 229920002451 polyvinyl alcohol Polymers 0.000 description 12
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000007062 hydrolysis Effects 0.000 description 11
- 238000006460 hydrolysis reaction Methods 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 239000004372 Polyvinyl alcohol Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 239000004014 plasticizer Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 238000006359 acetalization reaction Methods 0.000 description 8
- 229940022663 acetate Drugs 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 7
- 0 [2*][Si]([3*])([1*]C)O[4*] Chemical compound [2*][Si]([3*])([1*]C)O[4*] 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000003999 initiator Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229910052749 magnesium Inorganic materials 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 239000003505 polymerization initiator Substances 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- 239000011591 potassium Substances 0.000 description 7
- 229910052700 potassium Inorganic materials 0.000 description 7
- 125000005373 siloxane group Chemical group [SiH2](O*)* 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 150000003751 zinc Chemical class 0.000 description 7
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 6
- 239000004593 Epoxy Substances 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
- 238000009833 condensation Methods 0.000 description 6
- 230000005494 condensation Effects 0.000 description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 229960001549 ropivacaine Drugs 0.000 description 6
- 125000003107 substituted aryl group Chemical group 0.000 description 6
- 239000011787 zinc oxide Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 125000003700 epoxy group Chemical group 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229960004288 levobupivacaine Drugs 0.000 description 5
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical group O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000000516 sunscreening agent Substances 0.000 description 5
- ISPWSRVEMSGMKS-UHFFFAOYSA-N 3-[[3-hydroxypropyl(dimethyl)silyl]oxy-dimethylsilyl]propan-1-ol Chemical compound OCCC[Si](C)(C)O[Si](C)(C)CCCO ISPWSRVEMSGMKS-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000008064 anhydrides Chemical group 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229960001747 cinchocaine Drugs 0.000 description 4
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 4
- OYWALDPIZVWXIM-UHFFFAOYSA-N dimethyl-[3-(oxiran-2-ylmethoxy)propyl]-trimethylsilyloxysilane Chemical compound C[Si](C)(C)O[Si](C)(C)CCCOCC1CO1 OYWALDPIZVWXIM-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 235000013980 iron oxide Nutrition 0.000 description 4
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 4
- 229960004194 lidocaine Drugs 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 3
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 3
- GXDMUOPCQNLBCZ-UHFFFAOYSA-N 3-(3-triethoxysilylpropyl)oxolane-2,5-dione Chemical compound CCO[Si](OCC)(OCC)CCCC1CC(=O)OC1=O GXDMUOPCQNLBCZ-UHFFFAOYSA-N 0.000 description 3
- DNNFJTRYBMVMPE-UHFFFAOYSA-N 4-[[3-carboxypropyl(dimethyl)silyl]oxy-dimethylsilyl]butanoic acid Chemical compound OC(=O)CCC[Si](C)(C)O[Si](C)(C)CCCC(O)=O DNNFJTRYBMVMPE-UHFFFAOYSA-N 0.000 description 3
- OWJKJLOCIDNNGJ-UHFFFAOYSA-N 4-[[4-hydroxybutyl(dimethyl)silyl]oxy-dimethylsilyl]butan-1-ol Chemical compound OCCCC[Si](C)(C)O[Si](C)(C)CCCCO OWJKJLOCIDNNGJ-UHFFFAOYSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 208000031650 Surgical Wound Infection Diseases 0.000 description 3
- MFIBZDZRPYQXOM-UHFFFAOYSA-N [dimethyl-[3-(oxiran-2-ylmethoxy)propyl]silyl]oxy-dimethyl-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound C1OC1COCCC[Si](C)(C)O[Si](C)(C)CCCOCC1CO1 MFIBZDZRPYQXOM-UHFFFAOYSA-N 0.000 description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002318 adhesion promoter Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- UHHXUPJJDHEMGX-UHFFFAOYSA-K azanium;manganese(3+);phosphonato phosphate Chemical compound [NH4+].[Mn+3].[O-]P([O-])(=O)OP([O-])([O-])=O UHHXUPJJDHEMGX-UHFFFAOYSA-K 0.000 description 3
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- SWUIQEBPZIHZQS-UHFFFAOYSA-N calone Chemical compound O1CC(=O)COC2=CC(C)=CC=C21 SWUIQEBPZIHZQS-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229910001867 inorganic solvent Inorganic materials 0.000 description 3
- 239000003049 inorganic solvent Substances 0.000 description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 3
- 229940011051 isopropyl acetate Drugs 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- SWGZAKPJNWCPRY-UHFFFAOYSA-N methyl-bis(trimethylsilyloxy)silicon Chemical compound C[Si](C)(C)O[Si](C)O[Si](C)(C)C SWGZAKPJNWCPRY-UHFFFAOYSA-N 0.000 description 3
- 125000000962 organic group Chemical group 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 150000003014 phosphoric acid esters Chemical class 0.000 description 3
- 230000001699 photocatalysis Effects 0.000 description 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 3
- 229960004919 procaine Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000005871 repellent Substances 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- QNODIIQQMGDSEF-UHFFFAOYSA-N (1-hydroxycyclohexyl)-phenylmethanone Chemical compound C=1C=CC=CC=1C(=O)C1(O)CCCCC1 QNODIIQQMGDSEF-UHFFFAOYSA-N 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- GJKGAPPUXSSCFI-UHFFFAOYSA-N 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone Chemical compound CC(C)(O)C(=O)C1=CC=C(OCCO)C=C1 GJKGAPPUXSSCFI-UHFFFAOYSA-N 0.000 description 2
- HRQDDZWMEGEOOO-UHFFFAOYSA-N 2-trimethylsilylpropanoic acid Chemical compound OC(=O)C(C)[Si](C)(C)C HRQDDZWMEGEOOO-UHFFFAOYSA-N 0.000 description 2
- PMJIKKNFJBDSHO-UHFFFAOYSA-N 3-[3-aminopropyl(diethoxy)silyl]oxy-3-methylpentane-1,5-diol Chemical compound NCCC[Si](OCC)(OCC)OC(C)(CCO)CCO PMJIKKNFJBDSHO-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 229920001651 Cyanoacrylate Polymers 0.000 description 2
- NUPSHWCALHZGOV-UHFFFAOYSA-N Decyl acetate Chemical compound CCCCCCCCCCOC(C)=O NUPSHWCALHZGOV-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 229920001732 Lignosulfonate Chemical class 0.000 description 2
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 2
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003568 Sodium, potassium and calcium salts of fatty acids Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 229910021536 Zeolite Inorganic materials 0.000 description 2
- HITZGLBEZMKWBW-UHFFFAOYSA-N ac1n8rtr Chemical group C1CC2OC2CC1CC[Si](O1)(O2)O[Si](O3)(C4CCCC4)O[Si](O4)(C5CCCC5)O[Si]1(C1CCCC1)O[Si](O1)(C5CCCC5)O[Si]2(C2CCCC2)O[Si]3(C2CCCC2)O[Si]41C1CCCC1 HITZGLBEZMKWBW-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 150000001450 anions Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GVYJNBPRFDRDPE-UHFFFAOYSA-N bis[[dimethyl-[3-(oxiran-2-ylmethoxy)propyl]silyl]oxy]-methyl-phenylsilane Chemical compound C1OC1COCCC[Si](C)(C)O[Si](C)(C=1C=CC=CC=1)O[Si](C)(C)CCCOCC1CO1 GVYJNBPRFDRDPE-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229960003150 bupivacaine Drugs 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000006229 carbon black Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 238000001723 curing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- OTARVPUIYXHRRB-UHFFFAOYSA-N diethoxy-methyl-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CCO[Si](C)(OCC)CCCOCC1CO1 OTARVPUIYXHRRB-UHFFFAOYSA-N 0.000 description 2
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- HHBOIIOOTUCYQD-UHFFFAOYSA-N ethoxy-dimethyl-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CCO[Si](C)(C)CCCOCC1CO1 HHBOIIOOTUCYQD-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Chemical class 0.000 description 2
- 229930195729 fatty acid Chemical class 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 150000002373 hemiacetals Chemical class 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 229920005610 lignin Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 2
- 229960002409 mepivacaine Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 108700005457 microfibrillar Proteins 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 229910003455 mixed metal oxide Inorganic materials 0.000 description 2
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 2
- 229960003940 naproxen sodium Drugs 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 2
- YLYBTZIQSIBWLI-UHFFFAOYSA-N octyl acetate Chemical compound CCCCCCCCOC(C)=O YLYBTZIQSIBWLI-UHFFFAOYSA-N 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000010399 physical interaction Effects 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 239000004627 regenerated cellulose Substances 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229940100890 silver compound Drugs 0.000 description 2
- 150000003379 silver compounds Chemical class 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- JXUKBNICSRJFAP-UHFFFAOYSA-N triethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CCO[Si](OCC)(OCC)CCCOCC1CO1 JXUKBNICSRJFAP-UHFFFAOYSA-N 0.000 description 2
- HHPPHUYKUOAWJV-UHFFFAOYSA-N triethoxy-[4-(oxiran-2-yl)butyl]silane Chemical compound CCO[Si](OCC)(OCC)CCCCC1CO1 HHPPHUYKUOAWJV-UHFFFAOYSA-N 0.000 description 2
- YSIQPJVFCSCUMU-UHFFFAOYSA-N trimethyl-[methyl-[3-(oxiran-2-ylmethoxy)propyl]-trimethylsilyloxysilyl]oxysilane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)CCCOCC1CO1 YSIQPJVFCSCUMU-UHFFFAOYSA-N 0.000 description 2
- LZWMWONAYYGKMP-UHFFFAOYSA-N trimethyl-[methyl-bis[2-(7-oxabicyclo[4.1.0]heptan-4-yl)ethyl]silyl]oxysilane Chemical compound C1CC2OC2CC1CC[Si](C)(O[Si](C)(C)C)CCC1CC2OC2CC1 LZWMWONAYYGKMP-UHFFFAOYSA-N 0.000 description 2
- 239000010457 zeolite Substances 0.000 description 2
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- YNDGLMYLSGEDHX-UHFFFAOYSA-N 1,2,4,3-trioxathiane 3,3-dioxide Chemical compound O=S1(=O)OCCOO1 YNDGLMYLSGEDHX-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- JKTAIYGNOFSMCE-UHFFFAOYSA-N 2,3-di(nonyl)phenol Chemical compound CCCCCCCCCC1=CC=CC(O)=C1CCCCCCCCC JKTAIYGNOFSMCE-UHFFFAOYSA-N 0.000 description 1
- FSWLUYQMFPBXSH-UHFFFAOYSA-N 2,4,7,9-tetramethyldec-5-yne-1,1-diol Chemical compound CC(C)CC(C)C#CC(C)CC(C)C(O)O FSWLUYQMFPBXSH-UHFFFAOYSA-N 0.000 description 1
- LXOFYPKXCSULTL-UHFFFAOYSA-N 2,4,7,9-tetramethyldec-5-yne-4,7-diol Chemical compound CC(C)CC(C)(O)C#CC(C)(O)CC(C)C LXOFYPKXCSULTL-UHFFFAOYSA-N 0.000 description 1
- PXVVQEJCUSSVKQ-XWVZOOPGSA-N 2-(2-hydroxyethoxy)ethyl (1r,4ar,4br,10ar)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylate Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(=O)OCCOCCO PXVVQEJCUSSVKQ-XWVZOOPGSA-N 0.000 description 1
- GCDUWJFWXVRGSM-UHFFFAOYSA-N 2-[2-(2-heptanoyloxyethoxy)ethoxy]ethyl heptanoate Chemical compound CCCCCCC(=O)OCCOCCOCCOC(=O)CCCCCC GCDUWJFWXVRGSM-UHFFFAOYSA-N 0.000 description 1
- GEUJBNFWUQZXMZ-UHFFFAOYSA-N 2-[hexadecanoyl(methyl)amino]ethanesulfonic acid;sodium Chemical compound [Na].CCCCCCCCCCCCCCCC(=O)N(C)CCS(O)(=O)=O GEUJBNFWUQZXMZ-UHFFFAOYSA-N 0.000 description 1
- WBIQQQGBSDOWNP-UHFFFAOYSA-N 2-dodecylbenzenesulfonic acid Chemical compound CCCCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O WBIQQQGBSDOWNP-UHFFFAOYSA-N 0.000 description 1
- CYEJMVLDXAUOPN-UHFFFAOYSA-N 2-dodecylphenol Chemical compound CCCCCCCCCCCCC1=CC=CC=C1O CYEJMVLDXAUOPN-UHFFFAOYSA-N 0.000 description 1
- DGKXDLCVQSQVBC-UHFFFAOYSA-N 3,5,5-trimethylhexyl acetate Chemical compound CC(C)(C)CC(C)CCOC(C)=O DGKXDLCVQSQVBC-UHFFFAOYSA-N 0.000 description 1
- NHWJLCJXIBETKO-UHFFFAOYSA-N 3-phenoxybenzene-1,2-disulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC(OC=2C=CC=CC=2)=C1S(O)(=O)=O NHWJLCJXIBETKO-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- XKKTWZRDROMNNJ-UHFFFAOYSA-N CN(C)(C)C Chemical compound CN(C)(C)C XKKTWZRDROMNNJ-UHFFFAOYSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
- RUPBZQFQVRMKDG-UHFFFAOYSA-M Didecyldimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC RUPBZQFQVRMKDG-UHFFFAOYSA-M 0.000 description 1
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- ZSILVJLXKHGNPL-UHFFFAOYSA-L S(=S)(=O)([O-])[O-].[Ag+2] Chemical compound S(=S)(=O)([O-])[O-].[Ag+2] ZSILVJLXKHGNPL-UHFFFAOYSA-L 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- FRQDZJMEHSJOPU-UHFFFAOYSA-N Triethylene glycol bis(2-ethylhexanoate) Chemical compound CCCCC(CC)C(=O)OCCOCCOCCOC(=O)C(CC)CCCC FRQDZJMEHSJOPU-UHFFFAOYSA-N 0.000 description 1
- 238000003848 UV Light-Curing Methods 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 235000012544 Viola sororia Nutrition 0.000 description 1
- 241001106476 Violaceae Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- 239000011354 acetal resin Substances 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- ZCZSIDMEHXZRLG-UHFFFAOYSA-N acetic acid heptyl ester Natural products CCCCCCCOC(C)=O ZCZSIDMEHXZRLG-UHFFFAOYSA-N 0.000 description 1
- 125000004018 acid anhydride group Chemical group 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000033 alkoxyamino group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- 229940052294 amide local anesthetics Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 229940007550 benzyl acetate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- ZFMQKOWCDKKBIF-UHFFFAOYSA-N bis(3,5-difluorophenyl)phosphane Chemical compound FC1=CC(F)=CC(PC=2C=C(F)C=C(F)C=2)=C1 ZFMQKOWCDKKBIF-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229940043232 butyl acetate Drugs 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960000228 cetalkonium chloride Drugs 0.000 description 1
- QDYLMAYUEZBUFO-UHFFFAOYSA-N cetalkonium chloride Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 QDYLMAYUEZBUFO-UHFFFAOYSA-N 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 229960003431 cetrimonium Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 150000001793 charged compounds Polymers 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940038469 collagen hemostat Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229940100539 dibutyl adipate Drugs 0.000 description 1
- 229960004670 didecyldimethylammonium chloride Drugs 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- DLTISZOGPVEGJT-UHFFFAOYSA-L disodium;4-dodecyl-3-phenoxybenzene-1,2-disulfonate Chemical compound [Na+].[Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C(S([O-])(=O)=O)=C1OC1=CC=CC=C1 DLTISZOGPVEGJT-UHFFFAOYSA-L 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 229940060296 dodecylbenzenesulfonic acid Drugs 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 229960001859 domiphen bromide Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002118 epoxides Chemical group 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- JPXGPRBLTIYFQG-UHFFFAOYSA-N heptan-4-yl acetate Chemical compound CCCC(CCC)OC(C)=O JPXGPRBLTIYFQG-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940048866 lauramine oxide Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000004611 light stabiliser Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229960002285 methylbenzethonium chloride Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical class [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000013047 polymeric layer Substances 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 235000013966 potassium salts of fatty acid Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- RQFVHGAXCJVPBZ-UHFFFAOYSA-N propylene pentamer Chemical class CC=C.CC=C.CC=C.CC=C.CC=C RQFVHGAXCJVPBZ-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 239000005336 safety glass Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical class [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000013875 sodium salts of fatty acid Nutrition 0.000 description 1
- VHLNIHHHIKWTMJ-RSAXXLAASA-M sodium;(2s)-1-dodecoxy-3-oxidosulfonothioyloxypropan-2-ol Chemical compound [Na+].CCCCCCCCCCCCOC[C@H](O)COS([O-])(=O)=S VHLNIHHHIKWTMJ-RSAXXLAASA-M 0.000 description 1
- PYODKQIVQIVELM-UHFFFAOYSA-M sodium;2,3-bis(2-methylpropyl)naphthalene-1-sulfonate Chemical compound [Na+].C1=CC=C2C(S([O-])(=O)=O)=C(CC(C)C)C(CC(C)C)=CC2=C1 PYODKQIVQIVELM-UHFFFAOYSA-M 0.000 description 1
- IQKGZBVSMUUTQW-UHFFFAOYSA-M sodium;2-(4-methylpentyl)-3-propan-2-ylnaphthalene-1-sulfonate Chemical compound [Na+].C1=CC=CC2=C(S([O-])(=O)=O)C(CCCC(C)C)=C(C(C)C)C=C21 IQKGZBVSMUUTQW-UHFFFAOYSA-M 0.000 description 1
- CAVXVRQDZKMZDB-UHFFFAOYSA-M sodium;2-[dodecanoyl(methyl)amino]ethanesulfonate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CCS([O-])(=O)=O CAVXVRQDZKMZDB-UHFFFAOYSA-M 0.000 description 1
- IZWPGJFSBABFGL-GMFCBQQYSA-M sodium;2-[methyl-[(z)-octadec-9-enoyl]amino]ethanesulfonate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)N(C)CCS([O-])(=O)=O IZWPGJFSBABFGL-GMFCBQQYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940006295 sulfonated oleic acid Drugs 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 238000012719 thermal polymerization Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
- 239000012463 white pigment Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/34—Shaped forms, e.g. sheets, not provided for in any other sub-group of this main group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/28—Zirconium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8129—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers or esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers, e.g. polyvinylmethylether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8135—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an acyloxy radical of a saturated carboxylic acid, of carbonic acid or of a haloformic acid; Compositions of derivatives of such polymers, e.g. vinyl esters (polyvinylacetate)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q13/00—Formulations or additives for perfume preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/54—Silicon-containing compounds
- C08K5/541—Silicon-containing compounds containing oxygen
- C08K5/5415—Silicon-containing compounds containing oxygen containing at least one Si—O bond
- C08K5/5419—Silicon-containing compounds containing oxygen containing at least one Si—O bond containing at least one Si—C bond
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/54—Silicon-containing compounds
- C08K5/541—Silicon-containing compounds containing oxygen
- C08K5/5435—Silicon-containing compounds containing oxygen containing oxygen in a ring
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/04—Polysiloxanes
- C08G77/14—Polysiloxanes containing silicon bound to oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/04—Polysiloxanes
- C08G77/22—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen
- C08G77/26—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen nitrogen-containing groups
Definitions
- the present disclosure relates generally to compositions and methods for cosmetic, medical and personal care.
- Film forming materials have broad use in therapeutic, cosmetic and personal care applications. Such materials are used to coat a body surface, such as skin, nail and hair, for the protection of the surface or to apply therapeutic or cosmetic ingredients to the surface.
- the film forming process typically involves a chemical reaction and solvent evaporation.
- the chemical reaction such as polymerization of cyanoacrylate, can be quickly initiated by water or keratinous protein and forms a polymeric film on a surface.
- the chemical reaction may be epoxy-curing, UV or thermal polymerization of unsaturated monomers, radiation-induced curing or other ring-opening reactions.
- Solvent evaporation can help form a uniform layer of film on the surface.
- Water is widely used as a non-toxic solvent or as a dispersing medium as in the cases for latex and dispersions.
- Alcoholic solvents are another group of solvents, although many film forming materials have limited or no solubility in these solvents.
- organic solvents include alkyl acetate, acetone and toluene.
- compositions, kits and methods of preparing a biocompatible film for cosmetic or medical uses contain polyvinyl acetal (PVA), siloxane and a solvent. Once the solvent content is reduced, for instance, by evaporation, the mixture of PVA and siloxane is solidified, forming a film.
- the compositions and kits optionally, further include one or more of an antimicrobial agent, a pigment, an anti-inflammatory agent, an anesthetic agent or a hemostatic agent.
- Polyvinyl acetals have been used in the production of safety glass in automotive construction and for architectural uses.
- Plasticized polyvinyl butyral films, for example, are used as an intermediate layer in glazing units.
- plasticizers and adhesion promoters are sometimes added to PVA to provide better adhesion.
- plasticizers and adhesion promoters are either not suitable for human use.
- certain such films show coloration due to yellowing of aminosilanes and their unpleasant odor and skin-irritant action, a known problem when using amino-functional compounds.
- plasticizers are used to make the film flexible, it inevitably weakens adhesion between the film and skin, due to the lack of strong interactions with skin.
- compositions can also include therapeutic or cosmetic ingredients, enabling a broad range of applications in personal care.
- Such compositions can form a film that can be used, for example, in the form of an antimicrobial sealant, a liquid bandage, body paints, scar camouflage, water-proof sun block, makeup sealer, or antimicrobial wipe or spray.
- the present disclosure provides, in one embodiment, a composition comprising polyvinyl acetal (PVA) and siloxane, wherein the siloxane comprises a hydrophilic group.
- the siloxane comprises a functional group or a polar group.
- the composition further comprises a solvent.
- the hydrophilic group comprises one or more of the group of a halogen, oxygen, nitrogen, sulfur or phosphorus. In another aspect, the hydrophilic group is one or more of the group of a carboxylic acid, an amino group, a hydroxyl group, an epoxy group or an anhydride group.
- hydrophilic group examples include, without limitation,
- the siloxane has a structure of:
- the PVA has a molecular weight from about 25,000 to about 250,000, or alternatively from about 50,000 to about 200,000, or alternatively from about 75,000 to about 175000, or alternatively from about 100,000 to about 150,000.
- the PVA has a degree of polymerization of from about 200 to about 2,000, or alternatively from about 300 to about 1500, or alternatively from about 400 to about 1200, or alternatively from about 400 to about 800.
- the PVA has a degree of hydrolysis greater than about 70 mol %, or alternatively about 80 mol %, or about 85 mol %, or about 90 mo %, or about 95 mol %, or about 98 mol %, or about 99 mol %.
- the PVA has a structure of:
- R is selected from the group of methyl, ethyl, propyl, butyl, hexyl or benzyl
- A is an integer in the range of from about 50 to about 1800
- B is an integer in the range of from about 10 to about 800
- C is an integer from the range of from about 0 to about 1000.
- the PVA comprises polyvinyl butyral (PVB).
- the PVB constitutes about 70% to about 90% by weight of the PVA.
- the PVA has a concentration of from about 0.1 wt/vol % to about 60 wt/vol % in the composition, or alternatively from about 1 wt/vol % to about 30 wt/vol % in the composition, or alternatively from about 2 wt/vol % to about 25 wt/vol % in the composition, or alternatively from about 5 wt/vol % to about 20 wt/vol % in the composition, or alternatively from about 10 wt/vol % to about 15 wt/vol % in the composition.
- the solvent in the composition can be an inorganic solvent or an organic solvent.
- inorganic solvent include water, saline or combinations thereof.
- organic solvent includes one or more of the group of methanol, ethanol, isopropanol, n-propanol, butanol, methyl cellosolve, butyl cellosolve, methyl acetate, ethyl acetate, isopropyl acetate, butyl acetate, acetone, methyl ethyl ketone, toluene, xylene, dichloromethane or chloroform.
- the composition further comprises an antimicrobial agent.
- the antimicrobial agent can be one or more of the group of silver compounds, quaternary ammonium cations, or acid-anionic surfactants.
- the composition further comprises a pigment, such as, but not limited to, iron oxides, titanium dioxides, extender pigments ultramarine pigments, manganese violet, mixed metal oxide pigments, fluorescent pigments, carbon black, magnetite, lodestone, or magnetic iron oxide.
- a pigment such as, but not limited to, iron oxides, titanium dioxides, extender pigments ultramarine pigments, manganese violet, mixed metal oxide pigments, fluorescent pigments, carbon black, magnetite, lodestone, or magnetic iron oxide.
- the composition further comprises an anti-inflammatory agent.
- anti-inflammatory agent include, without limitation, ibuprofen, naproxen sodium, aspirin, ketoprofen, procaine, cocaine, lidocaine, priocaine, bupivacaine, levobupivacaine, ropivacaine or dibucaine.
- composition that further comprises an anesthetic agent.
- the anesthetic agent is one or more of the group of lidocaine, prilocalne, bupivicaine, levobupivacaine, ropivacaine, mepivacaine or dibucaine.
- composition further comprising a hemostatic agent.
- the hemostatic agent is one or more of the group of oxidized regenerated cellulose, gelatin, fibrin, thrombin, alginate, zeolite, collagen or chitosan.
- composition of any of the above embodiment can be provided in a solid, gel or liquid form, can be prepared in a form that is pharmaceutically acceptable.
- the present disclosure provides a composition prepared by admixing PVA and siloxane in a solvent, wherein the siloxane comprises a hydrophilic group.
- a composition prepared by admixing PVA and siloxane in a solvent wherein the siloxane comprises a hydrophilic group.
- PVA, siloxane, solvent and hydrophilic group are provided above and generally in the disclosure.
- the solvent is reduced by evaporation.
- Kits are also provided, comprising, in two or more separate compartments, polyvinyl acetal (PVA), siloxane and a solvent.
- the kit further comprises one or more of an antimicrobial agent, a pigment, an anti-inflammatory agent, an anesthetic agent or a hemostatic agent.
- the present disclosure also provides, in one embodiment, a method of preparing a film on a skin, comprising applying a suitable amount of a composition of any of the above embodiments on the skin and allowing the solvent to evaporate.
- a method of preparing an antimicrobial sealant on a skin comprising applying a suitable amount of a composition of the present disclosure on the skin and allowing the solvent to evaporate.
- a method of preparing a body paint on a skin comprising applying a suitable amount of a composition of the present disclosure on the skin and allowing the solvent to evaporate
- a film includes a single film as well as a plurality of films, including mixtures thereof.
- compositions and methods include the recited elements, but not excluding others.
- Consisting essentially of when used to define compositions and methods, shall mean excluding other elements of any essential significance to the composition or method.
- Consisting of shall mean excluding more than trace elements of other ingredients for claimed compositions and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention. Accordingly, it is intended that the methods and compositions can include additional steps and components (comprising) or alternatively including steps and compositions of no significance (consisting essentially of) or alternatively, intending only the stated method steps or compositions (consisting of).
- Aromatic indicates that each of ring atoms is essentially in the same plane and has a p-orbital perpendicular to the ring plane, and in which (4n+2) m electrons, when n is 0 or a positive integer, are associated with the ring to comply with Huckel's rule.
- Aromatic ring systems may be depicted as a circle, which represents the (4n+2) m electrons, enclosed by an outer cyclic structure, such as, a hexagon or pentagon.
- each of the rings in the compound of Formula I is aromatic.
- Alkyl refers to monovalent saturated aliphatic hydrocarbyl groups having from 1 to 10 carbon atoms and, in some embodiments, from 1 to 6 carbon atoms.
- C x-y alkyl refers to alkyl groups having from x to y carbon atoms.
- This term includes, by way of example, linear and branched hydrocarbyl groups such as methyl (CH 3 —), ethyl (CH 3 CH 2 —), n-propyl (CH 3 CH 2 CH 2 —), isopropyl ((CH 3 ) 2 CH—), n-butyl (CH 3 CH 2 CH 2 CH 2 —), isobutyl ((CH 3 ) 2 CHCH 2 —), sec-butyl ((CH 3 )(CH 3 CH 2 )CH—), t-butyl ((CH 3 ) 3 C—), n-pentyl (CH 3 CH 2 CH 2 CH 2 CH 2 —), and neopentyl ((CH 3 ) 3 CCH 2 —).
- linear and branched hydrocarbyl groups such as methyl (CH 3 —), ethyl (CH 3 CH 2 —), n-propyl (CH 3 CH 2 CH 2 —), isopropyl ((CH 3 ) 2 CH—),
- “Lower alkyl” refers to an alkyl with from 1 to 6 carbon atoms.
- Alkoxy refers to the group —O-alkyl wherein alkyl is defined herein. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy, and n-pentoxy.
- “Lower alkoxy” refers to an alkoxy with from 1 to 6 carbon atoms.
- Amino refers to the group —NH 2 .
- Haldroxyamino refers to the group —NHOH.
- Alkoxyamino refers to the group —NHO-alkyl wherein alkyl is defined herein.
- Epoxy refers to a group continaing an oxygen atom joined by single bonds to two adjacent carbon atoms, thus forming the three-membered epoxide ring.
- Anhydride refers to a group having two acyl groups bound to the same oxygen atom.
- Moliec anhydride refers to the acid anhydride group of malice acid.
- Carboxyl refers to —COOH or salts thereof.
- halogen refers to fluoro, bromo, chloro, and iodo.
- “Hydroxy” or “hydroxyl” refers to the group —OH.
- Niro refers to the group —NO 2 .
- Thiol refers to the group —SH.
- “Compound” and “compounds” as used herein refers to a compound encompassed by the generic formulae disclosed herein, any subgenus of those generic formulae, and any forms of the compounds within the generic and subgeneric formulae, including the racemates, stereoisomers, and tautomers of the compound or compounds.
- Stereoisomer or “stereoisomers” refer to compounds that differ in the chirality of one or more stereocenters. Stereoisomers include enantiomers and diastereomers.
- Tautomer refer to alternate forms of a compound that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or the tautomeric forms of heteroaryl groups containing a ring atom attached to both a ring —NH— moiety and a ring ⁇ N— moiety such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles.
- arylalkyloxycabonyl refers to the group (aryl)-(alkyl)-O—C(O)—.
- impermissible substitution patterns e.g., methyl substituted with 5 fluoro groups.
- impermissible substitution patterns are well known to the skilled artisan.
- hydrophilic group refers to a group that is attracted to, and tends to be dissolved by water.
- a hydrophilic group has a tendency to interact with or be dissolved by water and other polar substances.
- a hydrophilic group is charge-polarized and capable of hydrogen bonding, enabling it to dissolve more readily in water than in oil or other hydrophobic solvents. Hydrophilic and hydrophobic molecules are also known as polar molecules and nonpolar molecules, respectively.
- a “polar group” refers to a chemical group in which the distribution of electrons is uneven enabling it to take part in electrostatic interactions.
- Polymerization initiator refers to an agent that promotes initiation of a polymerization reaction.
- a polymerization initiator in one aspect, reacts with a monomer to form an intermediate compound capable of linking successively with a large number of other monomers into a polymeric compound.
- One type of initiators produce free radicals, such as peroxides and aliphatic azo compounds used to polymerize vinyl chloride, methyl methacrylate, and other monomers.
- a polymerization initiator is an anion.
- a polymerization initiator is a photoactive initiator, such as but not limited to alpha hydroxyketone, like Irgacure 184, Irgacure 2959 or DAROCUR®1173 from Ciba Specialty Chemicals Inc.
- “Degree of polymerization” or “DP” refers to the number of monomeric units in a macromolecule or polymer or oligomer molecule. For a homopolymer, there is only one type of monomeric unit and the number-average degree of polymerization is given by total molecular weight divided by molecular weight of the monomer unit. For a copolymer, DP refers to the number of repeat units.
- “Degree of hydrolysis” refers to the fraction of a compound, which has undergone hydrolysis at equilibrium. Hydrolysis is a chemical reaction of one compound with water, often resulting in the formation of one or more new compounds. For polyvinyl acetal, degree of hydrolysis is the percentage of dangling acetate on the polymer backbone, which has hydrolyzed to form dangling hydroxyl groups and free acetate.
- Degree of acetalization refers to the molar percentage of hydroxyl group substitution via acetalization with aldehyde during the synthesis of polyvinyl acetal.
- the present disclosure provides film forming compositions.
- the compositions can be non-toxic, coatable and sprayable. After application, the compositions can form flexible films quickly.
- the film can chemically react with skin, adhere to skin for prolonged time of period.
- Another advantage is that the composition can accommodate active ingredients, such as drugs, pigments, inorganic particles and antimicrobial agents for killing bacteria and viruses.
- the present disclosure provides, in one embodiment, a composition comprising, or alternatively consisting essentially of, or alternatively consisting of, polyvinyl acetal (PVA) and siloxane, wherein the siloxane comprises a hydrophilic group.
- the siloxane comprises a functional group or a polar group.
- the composition further comprises a solvent.
- PVA demonstrates outstanding adhesion to many surfaces, is compatible with active ingredients, chemically and thermally stable and non-toxic. PVA can form flexible and water-repellent films. It is also noted that PVA has good solubility in alcohol and lower alkyl acetate.
- PVA has long polymer chains, contributing to toughness combined with flexibility of the film.
- long polymer chains there are randomly distributed hydroxyl groups, acetate groups, and acetals, contributing to the outstanding binding efficiency and adhesion to a large number of surfaces because the hydroxyl groups, acetate groups and acetals interact with different groups on the surface for strong binding.
- the random distribution of the groups on the polymer chains minimizes the probability of crystallization, which in turn results in excellent optical clarity of the formed film.
- PVA films are characterized by high resistance to aliphatic hydrocarbons, mineral, animal and vegetable oils (with the exception of castor and blown oils).
- Acetals offer stability against all types of nucleophiles and bases and most oxidants, so long as the conditions do not lead to hydrolysis of the acetal. Additionally, acetals withstand strong alkalis but are subject to some attack by strong acids. The stability of PVA film contributes to the compatibility with other active ingredients. For example, when ethanol is as the solvent, the film forms quickly in a matter of seconds via ethanol evaporation.
- siloxane as a plasticizer, is introduced to make the film flexible and to increase the gas permeability of the resultant film, making the film breathable. This feature will ultimately bring comfort to consumer.
- siloxane is inherently inert and shows poor adhesion to most surfaces. It is therefore widely perceived that siloxane does not serve as a good plasticizer for a film forming composition, which forms films that need to adhere to a surface. This is because the introduction of siloxane would undoubtedly result in weakened adhesion of the resultant film to the surface.
- siloxane in the present technology, such negative effect of siloxane is eliminated by including one or more polar groups or alternatively hydrophilic groups into the siloxane.
- polar or hydrophilic groups help form either chemical bonds or strong electrostatic interactions with the surface such as skin. Chemical bonds are much stronger than physical interactions and thus can greatly enhance the adhesion.
- siloxane with polar or hydrophilic groups such as epoxy and maleic anhydride can be used as both a plasticizer and adhesion promoter.
- a polymerization initiator is a chemical that generate free radicals, such as peroxides and aliphatic azo compounds.
- UV curing formulations usually need photoactive initiators to generate the first batch of free radicals under UV lights for subsequent polymerization.
- UV initiators include alpha hydroxyketone, like Irgacure 184, Irgacure 2959 and DAROCUR®1173 from Ciba Specialty Chemicals Inc.
- Mammalian skin is composed of three primary layers: a. the epidermis, which provides waterproofing and serves as a barrier to infection; b. the dermis, which serves as a location for the appendages of skin; c. the hypodermis (subcutaneous adipose layer).
- Epidermis is the outermost layer of the skin. It forms the waterproof, protective wrap over the body's surface and is made up of stratified squamous epithelium with an underlying basal lamina.
- the epidermis can be further subdivided into the following strata (beginning with the outermost layer): corneum, lucidum (only in palms of hands and bottoms of feet), granulosum, spinosum, basale.
- Cells are formed through mitosis at the basale layer.
- the daughter cells move up the strata changing shape and composition as they die due to isolation from their blood source.
- the cytoplasm is released and the protein keratin is inserted. They eventually reach the corneum and slough off. This process is called keratinization and takes place within about 27 days.
- the stratum corneum has the following composition: cystine, 2.34%; tyrosine, 5.70%; histidine, 0.59%; lysine 3.08%; arginine, 10.01%.
- the primary amino group from lysine has great reactivity with epoxy and maleic anhydride under ambient conditions.
- lysine for instance, from the skin, can be employed to react with siloxane having the corresponding reactive or functional group which is polar or hydrophilic, for greatly enhanced adhesion.
- PVA polyvinyl acetals
- Polyvinyl alcohols are high molecular weight resins containing various percentages of hydroxyl and acetate groups produced by hydrolysis of polyvinyl acetate.
- the conditions of the acetal reaction and the concentration of the particular aldehyde and polyvinyl alcohol used are closely controlled to form polymers containing predetermined proportions of hydroxyl groups, acetate groups and acetal groups.
- the final product may be represented by the following stylized structure. The proportions of A, B and C are controlled, and they are randomly distributed along the molecule.
- R can be methyl, ethyl, propyl, butyl, hexyl, benzyl group and combinations thereof.
- A can be an integer in the range of from about 50 to about 1800, or from 100 to about 1000;
- B can be an integer in the range of from about 10 to about 800, or from about 100 to about 500;
- C can be an integer from the range of 0 to about 1000, or from about 100 to about 500.
- the polyvinyl alcohol has a molecular weight from about 25,000 to about 250,000, or alternatively from about 50,000 to about 200,000, or alternatively from about 75,000 to about 175000, or alternatively from about 100,000 to about 150,000.
- the polyvinyl alcohol has a degree of polymerization of from about 200 to about 2,000, or alternatively from about 300 to about 1500, or alternatively from about 400 to about 1200, or alternatively from about 400 to about 800.
- the polyvinyl alcohol has a degree of hydrolysis greater than about 70 mol %, or alternatively about 80 mol %, or about 85 mol %, or about 90 mol %, or about 95 mol %, or about 98 mol %, or about 99 mol %. In some aspects, the polyvinyl alcohol has a degree of hydrolysis that is lower than about 99.99 mol %, or alternatively lower than about 99.9 mol %, or alternatively lower than about 99 mol %, or alternatively lower than about 98 or 95 mol %. It is noted that when the degree of hydrolysis is too low, the solubility in water is low and polyvinyl alcohol is difficult to produce from it. On the other hand, polyvinyl alcohol having a too high degree of hydrolysis is difficult to produce.
- Polyvinyl alcohol can be acetalized into polyvinyl acetal under an acidic condition in an aqueous solvent according to a known method.
- the polyvinyl acetal thus obtained herein has a degree of acetalization of from about 45 to about 90 mol %.
- the degree of acetalization is from about 50 to about 85 mol %, or from about 55 to about 80 mol %, or from about 60 to about 75 mol %.
- Polyvinyl alcohol with too low a degree of acetalization is unfavorable since the powdery reaction product obtained through acetalization can be difficult to recover and since the waterproofness of the polyvinyl acetal obtained can be low or the compatibility of polyvinyl acetal with plasticizer can be low.
- the degree of acetalization of polyvinyl acetal is too high, the polyvinyl acetal of the type can be difficult to produce, and its compatibility with plasticizer may be lowered.
- the aldehyde compound to be used for the acetalization includes, for example, formaldehyde, acetaldehyde, propionaldehyde, butylaldehyde, hexylaldehyde and benzaldehyde. These may be used singly or as a mixture of two or more of them.
- the aldehyde compounds are alkyaldehyde having at most four carbon atoms and benzaldehyde and butylaldehyde are preferred.
- polyvinyl acetal resins like polyvinyl formal acetal and polyvinyl butyral.
- polyvinyl butyral resins are sold by Solutia under the name of Butvar®, and by Kuraray under the name of Mowital®.
- Butvar® B-72, B-74, B-76, B-79, B-90, and B-98 are polyvinyl butyrals with molecular weights between 40 and 250 kg/mol, butyral content expressed as % polyvinyl butyral between 80 and 88%; acetate content expressed as % polyvinyl acetate between 0.0 and 2.5%; hydroxyl content expressed as % polyvinyl alcohol between 11.5 and 20%.
- Mowital® B20H, B30T, B30H, B30HH, B45H, B60T, B60H, B60HH, and B75H have molecular weights from 20 to 100 kg/mol.
- PVA polyvinyl butyral
- a polyvinyl butyral content of between about 70 and about 90% weight of the total polymer is used.
- the content is from about 72 to about 85%, or from about 73 to about 80%, or about 75%.
- polyvinyl butyrals resins examples include butvar® B-72, Butvar® B-74, Butvar® B-76, Butvar® B-79 and Butvar® B-98.
- the content of PVB is preferably within a range of 0.1 wt/vol % to 60 wt/vol % based on the solvent, and more preferably within a range of 1-30 wt/vol % in view of the resultant film flexibility and adhesion to skin.
- a siloxane is any chemical compound composed of units of the form R 2 SiO, where R is a hydrogen atom or a hydrocarbon group, as well as their derivatives.
- Siloxanes can have branched or unbranched backbones consisting of alternating silicon and oxygen atoms —Si—O—Si—O—, with side chains R attached to the silicon atoms.
- the siloxane has a structure of:
- X is selected from the group consisting of an amino group, an epoxy group, a hydroxyl group, a carboxylic acid group, and a maleic anhydride group.
- R 1 is a divalent organic group optionally substituted with an oxygen, nitrogen, or sulfur atom, or is selected from the group consisting of a substituted or non-substituted C 2 -C 20 -aliphatic group, a substituted or non-substituted aromatic group, and a substituted or non-substituted aliphatic aromatic group.
- R 2 is selected from the group consisting of a lower alkyl group, a lower alkoxy group, and a polymeric siloxane group.
- R 3 is selected from the group consisting of a lower alkyl group, a lower alkoxy group, and a polymeric siloxane group.
- R 4 is selected from the group consisting of a lower alkyl group, an oligomeric or a polymeric siloxane group and
- the hydrophilic group comprises one or more of the group of halogen, oxygen, nitrogen, sulfur or phosphorus. In another aspect, the hydrophilic group is one or more of the group of a carboxylic acid, an amino group, a hydroxyl group, an epoxy group or an anhydride group.
- hydrophilic group examples include, without limitation,
- Siloxanes are commercially available from various vendors.
- the content of silanol groups in the siloxane after modification is preferably within a range of from 0.1 wt. % to 60 wt. % based on the resin so modified, and more preferably within a range of 3-40 wt. % in view of the processability and adhesion.
- the solvent in the disclosed compositions can be inorganic or organic.
- the organic solvent include, without limitation, alcohols such as methanol, ethanol, isopropanol, n-propanol, butanol; cellosolves such as methyl cellosolve, butyl cellosolve; ketones such as acetone, methyl ethyl ketone; aromatic hydrocarbons such as toluene, xylene; and halohydrocarbons such as dichloromethane, chloroform; alkyl acetate, such as methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate, amyl acetate, isoamyl acetate, heptyl acetate, octyl acetate, nonanyl acetate, decyl acetate; aromatic acetate, such as benzyl acetate
- ethanol is more preferred.
- Other examples include methanol, ethanol, isopropanol, n-propanol, butanol, methyl cellosolve, butyl cellosolve, alkyl acetate, acetone, methyl ethyl ketone, toluene, xylene, dichloromethane or chloroform.
- Non-limiting examples of inorganic solvent include water, saline or combinations thereof.
- the composition can contain any known ordinary additives such as UV absorbent, light stabilizer, antioxidant, surfactant, or colorant.
- plasticizers for polyvinyl acetals are tri or tetraethylene glycol dicarboxylates such as triethylene glycol di-2-ethylhexanoate, tetraethylene glycol di-2-ethylhexanoate, triethylene glycol di-n-heptanoate, tetraethylene glycol di-n-deptanoate; and dicarboxylates such as dioctyl adipate, dibutyl adipate, dioctyl phthalate and dibutyl phthalate. One or more of these may be used herein either singly or as combined.
- Antimicrobial agents are chemical compounds that destroy microbes, prevent their pathogenic action, or prevent their growth. Antimicrobial agents, often referred to as anti-infective agents, are frequently applied topically to the skin and mucous membranes in the form of a solution, cream, or ointment; appropriate formulations may be applied to wound and body cavities, and to the eyes, nose and mouth.
- antimicrobial agents include, without limitation, silver particles, silver compounds like silver chloride, silver acetate, silver oxide, silver sulfate, silver nitrate, silver thiosulfate and combinations thereof.
- the antimicrobial activity of inorganic substances is generally related to the ions into which they dissociate.
- the antimicrobial activity of various metal ions for example, is often attributed to their affinity for protein material and the insolubility of the metal proteinate formed.
- Quaternary ammonium cations also known as quats, another type of antimicrobial agent, are positively charged polyatomic ions of the structure NR 4 + , R being an alkyl group. Unlike the ammonium ion (NH 4 + ) and the primary, secondary, or tertiary ammonium cations, the quaternary ammonium cations are permanently charged, independent of the PH of their solution.
- Quaternary salts are another type of antimicrobial agents, with a general structure shown below:
- a 1 , A 2 , A 3 and A 4 can each be, independent of one another, hydrogen, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above. Also, any of the A 1 , A 2 , A 3 and A 4 substituents can be absent and any of the remaining substituents can be a multivalent group. Certain quaternary ammonium compounds, especially those containing long alkyl chains, are used as antimicrobials and disinfectants.
- Quaternary ammonium compounds are lethal to a wide variety of organisms except endospores, Mycobacterium tuberculosis , non-enveloped viruses, and Pseudomonas spp.
- Suitable surfactants may include sodium lauryl sulfate, linear alkylbenzene sulfonates, alcohol sulfates, alkyl sulfates, alkyl sulfonates, sodium alkyl methyltaurines, alpha-olefin sulfonates, alcohol ethoxylates, nonylphenyl ethoxylates, alkylpolyglucosides, fatty alcohols, fatty acids and fatty acid salts, lignosulfonates and lignin derivatives, hydroxypoly(oxyethylene) derivatives, fatty alkanolamides, fatty amine oxides, sodium dioctylsulfosuccinate, dodecylbenzene sulfonic acid and salts thereof, the sodium salt of sulfonated oleic acid, sodium dodecylbenzene sulfonate, la
- surfactants include alkyl(C8-C24) benzenesulfonic acid and its ammonium, calcium, magnesium, potassium, sodium, and zinc salts; alkyl(C8-C18) sulfate and its ammonium, calcium, isopropylamine, magnesium, potassium, sodium, and zinc salts; diethylene glycol abietate, lauryl alcohol, lignosulfonate and its ammonium, calcium, magnesium, potassium, sodium, and zinc salts; nonyl, decyl, and undecyl glycoside mixture with a mixture of nonyl, decyl, and undecyl oligosaccharides and related reaction products (primarily decanol and undecanol) produced as an aqueous based liquid (50 to 65% solids) from the reaction of primary alcohols (containing 15 to 20% secondary alcohol isomers) in a ratio of 20% C9, 40% C10, and 40% C11 with carbohydrates (average glucose to alkyl chain ratio 1.3 to 1.8);
- the surfactant may be one or more of the following alcohol ethoxylates: alpha-Alkyl(C9-C18-omega-hydroxypoly(oxyethylene) with polyoxyethylene content of 2-30 moles; .alpha.-(p-alkylphenyl)-omega.-hydroxypoly(oxyethylene) produced by the condensation of 1 mole of alkylphenol (alkyl is a mixture of propylene tetramer and pentamer isomers and averages C13) with 6 moles ethylene oxide; .alpha.-Alkyl(C6-C14-.omega.-hydroxypoly(oxypropyylene) block copolymer with polyoxyethylene; polyoxypropylene content is 1-3 moles; polyoxyethylene content is 4-12 moles; average molecular weight is approximately 635 amu; .alpha.-Alkyl (C12-C15-.omega.-hydroxypoly(oxypropyylene)poly
- a pigment is a colored, black, white, or fluorescent particulate organic or inorganic solid. These solids are usually insoluble in, and essentially physically and chemically unaffected by, the vehicle or substrate into which it is incorporated.
- FDA-approved pigments includes iron oxides, titanium dioxide, extender pigments ultramarine pigments, manganese violet, mixed metal oxide pigments, fluorescent pigments, carbon black, magnetite, lodestone, magnetic iron oxide. Ultramarine pigments are insoluble inorganic compounds that are available in a wide range of blue shades, green shades, violets, and pink.
- Manganese violet is FDA approved for cosmetic applications. It has excellent lightfastness (8) and bleed resistance (5).
- Zinc oxide is recognized as a mild antimicrobial, wound healing and sunscreen agent. It primarily absorbs UVA light rather than scattering or reflecting, non-irritating, non-comedogenic, and micronized by forming many small micro particles for cosmetic use. Titanium dioxide is derived from Titanium, a highly reflective white chalky mineral, non-irritating, non-comedogenic, micronized by forming many small micro particles for cosmetic use, listed in the FDA monograph as one of the top and most effective active ingredients for sun protection. Titanium dioxide is the most important white pigment currently produced commercially. The pigment is used in a wide range of applications including inks, textiles, paper, paints, food, and pharmaceuticals.
- Titanium dioxide is stable, nonvolatile, and largely insoluble. Regular titanium dioxide is highly stable under most conditions. However, it has some photocatalytic activity (i.e. promotes reactions between other chemicals), especially in direct sunlight. Titanium dioxide nanoparticles appear to have much greater photocatalytic activity than regular titanium dioxide powder and might trigger formation of harmful free radicals when exposed to sunlight. Most manufacturers of titanium dioxide nanoparticles coat them to reduce or eliminate such effects.
- Titanium dioxide is a physical sunscreen protecting against UVB and short UVA (a.k.a. UNA-1) light. It has a long history of seemingly safe use and is not irritating. Its disadvantages include unsightly whitish tint and insufficient protection against long UVA (a.k.a. UVA-2). It may also help generate harmful free radicals via photocatalytic mechanism when exposed to sunlight. These effects may not have significant impact in topical use but the issue needs to be researched. Nanoparticle forms of titanium dioxide are less unsightly but their potential risks are unclear and may be greater than those associated with regular forms. More research is clearly needed. To increase protection and extend its range, titanium dioxide is usually combined with chemical UVB and UVA blockers and/or zinc oxide.
- titanium dioxide-based sunscreens leave unsightly white residue.
- titanium dioxide creates stronger whitish tint than zinc oxide at comparable concentrations.
- This problem has been partly addressed by the advent of titanium dioxide nanoparticles as a sunscreen agent. Titanium dioxide nonoparticles have different optical properties and tend to produce much less whitish tint than regular powdered titanium dioxide.
- titanium dioxide nanoparticles retain the capacity to protect from UVB and short UVA (UVA-2) light.
- UVA-2 UVA
- the safety of titanium dioxide nanoparticles remains a controversial subject. When exposed to sunlight (and possibly even other light), titanium dioxide nanoparticles may promote generation of free radicals and increase the risk of mutations—more so that regular titanium dioxide.
- titanium dioxide nanoparticles administered orally to mice in water were shown to cause genetic damage, such as mutations and DNA breaks.
- this effect may not be relevant to topical use as long as titanium dioxide nanoparticles do not penetrate stratum corneum (the outer skin layer consisting mostly of dead cells).
- manufacturers typically cover titanium dioxide nanoparticles with special coating, which increases the stability and reduces photoreactivity of the particles.
- titanium dioxide nanoparticles could penetrate the skin, reach systemic circulation and accumulate in body organs. At present, there is no clear evidence that they do, but this is a valid concern that needs to be researched. Until then, it may be prudent to avoid the products with titanium dioxide nanoparticles (regular titanium dioxide should be ok).
- Titanium dioxide is in many ways similar to zinc dioxide as a sun blocking agent. However, zinc oxide has advantages of having broader range, anti-irritant properties and less opacity at comparable concentrations. In commercial sunscreens, titanium dioxide is usually combines with chemical UVB blockers. Sometimes it is also combined with other physical (zinc oxide) and/or chemical UVA blockers.
- Inflammation is the body's response to irritation or injury, and is characterized by redness, warmth, swelling, and pain.
- Anti-inflammatory refers to the property of a substance or treatment that reduces inflammation.
- Non-steroidal anti-inflammatory drugs (NSAIDs), alleviate pain by counteracting the cyclooxygenase (COX) enzyme. On its own COX enzyme synthesizes prostaglandins, creating inflammation. In whole the NSAIDs prevent the prostaglandins from ever being synthesized, reducing or eliminating the pain.
- COX cyclooxygenase
- Some common examples of NSAIDs are: aspirin, ibuprofen, and naproxen. NSAIDs are used to treat a variety of conditions that cause inflammation.
- NSAIDs are also used to treat pain from injury or other causes of long-term pain. NSAID can reduce inflammation and relieve pain, and these drugs include ibuprofen, naproxen sodium, aspirin, ketoprofen, procaine, cocaine, lidocaine, priocaine, bupivacaine, levobupivacaine, ropivacaine, and dibucaine.
- Local anesthetics are agents that prevent transmission of nerve impulses without causing unconsciousness. They act by binding to fast sodium channels from within (in an open state). Local anesthetics can be either ester or amide based. Ester local anesthetics (e.g., procaine, amethocaine, cocaine) are generally unstable in solution and fast-acting, and allergic reactions are common. Amide local anesthetics (e.g., lidocaine, prilocalne, bupivicaine, levobupivacaine, ropivacaine, mepivacaine and dibucaine) are generally heat-stable, with a long shelf life (around 2 years).
- Ester local anesthetics e.g., procaine, amethocaine, cocaine
- Amide local anesthetics e.g., lidocaine, prilocalne, bupivicaine, levobupivacaine, ropivacaine, mepivacaine and di
- levobupivacaine which is S( ⁇ )-bupivacaine
- ropivacaine S( ⁇ )-ropivacaine
- Antihemorrhagic agents used in medicine have various mechanisms of action.
- Systemic drugs work by inhibiting fibrinolysis or promoting coagulation.
- Locally-acting hemostatic agents work by causing vasoconstriction or promoting platelet aggregation.
- hemostatic materials including oxidized regenerated cellulose, gelatin, fibrin, thrombin, alginate, zeolite, collagen and chitosan.
- MCH microfibrillar collagen hemostat
- MCH microfibrillar collagen hemostat
- MCH collagen attracts and helps with the clotting process to eventually stop bleeding.
- the practical application for MCH is different from that of the hemostatic clamp. It is not possible, for example, to stop a severed artery from gushing blood by using a patch of MCH and wait for the clotting process.
- the blood vessel must be mechanically clamped and repaired.
- composition of any of the above embodiment can be provided in a gel, solid, or liquid form, can be prepared in a form that is pharmaceutically acceptable.
- the present disclosure provides a composition prepared by admixing PVA and siloxane in a solvent, wherein the siloxane comprises a hydrophilic group.
- a composition prepared by admixing PVA and siloxane in a solvent wherein the siloxane comprises a hydrophilic group.
- PVA, siloxane, solvent and hydrophilic group are provided above and generally in the disclosure.
- the solvent is reduced by evaporation.
- Kits are also provided, comprising, in two or more separate compartments, polyvinyl acetal (PVA), siloxane and a solvent.
- the kit further comprises one or more of an antimicrobial agent, a pigment, an anti-inflammatory agent, an anesthetic agent or a hemostatic agent.
- the present disclosure also provides, in one embodiment, a method of preparing a film on a skin, comprising applying a suitable amount of a composition of any of the above embodiments on the skin and allowing the solvent to evaporate.
- a method of preparing an antimicrobial sealant on a skin comprising applying a suitable amount of a composition of the present disclosure on the skin and allowing the solvent to evaporate.
- a method of preparing a body paint on a skin comprising applying a suitable amount of a composition of the present disclosure on the skin and allowing the solvent to evaporate.
- compositions or kits can be provided without the corresponding solvent.
- the solvent can be provided in a separate compartment or package.
- the compositions or kits contain all the recited ingredients without a solvent.
- the user can simply add a suitable amount of solvent to the composition or kit. Accordingly, relevant instructions can be provided, along with the compositions or kits.
- the solvent can be removed, or partially removed, from any of the compositions or kits, for the purpose of, e.g., storage or transportation. Removal of the solvent can be done with methods readily available in the art, as illustrated in Example 7, without allowing the composition to form a film during the process.
- freeze-drying also known as lyophilisation, lyophilization or cryodesiccation
- Freeze-drying works by freezing the material and then reducing the surrounding pressure and adding enough heat to allow the frozen water in the material to sublime directly from the solid phase to the gas phase.
- the original compositions can be regenerated by adding proper amount of solvent to these solid, semi-solid, or gel-like, components following the same procedures described in the invention. This regeneration of composition will not adversely affect the performance.
- compositions or kits without the solvent, are also provided.
- This example provides a antimicrobial sealant that can be useful, for example, for minimizing surgical site infections.
- the film-forming composition above quickly forms a thin, flexible film which bonds to the skin surface, including skin contours, hair follicles and sweat glands. This breathable film immobilizes bacteria which survive the conventional surgical skin preparation and rebound during surgery, preventing migration or transference into the incision.
- This film has a unique mechanism of action which reduces skin Row contamination by physically immobilizing microorganisms—not by antimicrobial activity. Using the film-forming composition as microbial sealant does not contribute to antimicrobial resistance, therefore.
- Liquid bandage is a typical film forming composition, which is a topical skin treatment for minor cuts and sores that is sold by several companies.
- the products are mixtures of chemicals which create a polymeric layer which binds to the skin. This protects the wound by keeping dirt and germs out, and keeping moisture in.
- liquid bandages are waterproof and germ-proof and can speed and enhance healing, and stay on for days.
- Liquid bandages can also be applied to some hard-to-reach areas, like the space between fingers.
- red pigment (Derma #17AA) was added.
- the formulation was then shaken well to form a stable dispersion.
- a water-repellent, breathable, non-tacky body paint was then fabricated with long-lasting time on skin.
- PVB (120000-150000 g/mol, Butvar® B-74 from Solutia, Inc.) was transferred to a flask (250 ml) filled with 200 proof ethanol (100 ml). The mixture was stirred for 5 hrs to dissolve all PVB particles. Then 2 g of 1,3-bis(hydroxypropyl)tetramethyldisiloxane was added to the solution above and the mixture was further stirred for 30 min.
- a makeup sealer is a water-resistant, anti-perspiring coating on a completed makeup.
- a perfume Calone or methylbenzodioxepinone, trade-named Calone 1951 from Pfizer Inc.
- a makeup sealer is created and can be sprayed to the final makeup to form a flexible, water-repellent film to bind the makeup onto skin even in a hot summer day or on heavily perspiring skins.
- Titanium oxide nano particles can disinfect or clean surfaces exposed to light, thus working as a bactericidal or photooxidizing agent.
- This formulation can clean soiling, control or suppress bacterial proliferation, and reduce the frequency of cleaning or disinfection in the food industry, kitchens, bathrooms, washrooms, hospitals, glazing and facades.
- PVB 170000-250000 g/mol, Butvar® B-72 from Solutia, Inc.
- a Spex Freezer/mill 6770 in liquid nitrogen for 10 cycles at default configuration by the manufacturer, each cycle lasting 3 minutes. Particles of about 5 ⁇ m ⁇ about 100 ⁇ m are generated.
- a solution of 1,3-bis(hydroxypropyl)tetramethyldisiloxane (0.4 g) in chloroform (2 ml) is introduced and mixed manually with a spatula for 2 minutes to create uniformly coated particles. Finally, the coated particles are dried under vacuum at ambient temperature for 4 hrs for use later.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Dentistry (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
Compositions, kits and methods of preparing a biocompatible film for cosmetic or medical uses are disclosed. The compositions or kits contain polyvinyl acetal (PVA), siloxane and a solvent. The siloxane can have a hydrophilic group. Once the solvent content is reduced, for instance, by evaporation, the mixture of PVA and siloxane is solidified, forming a film. The compositions and kits, optionally, further include one or more of an antimicrobial agent, a pigment, an anti-inflammatory agent, an anesthetic agent or a hemostatic agent. Such a film can be used, for example, in the form of an antimicrobial sealant, a liquid bandage, body paints, scar camouflage, water-proof sun block, makeup sealer, or antimicrobial wipe or spray.
Description
- This application is a continuation of U.S. application Ser. No. 13/696,726, filed Nov. 7, 2012, which application is a U.S. National Stage application under 35 U.S.C. §371 of International Application No. PCT/US2011/035785, filed May 9, 2011, which application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 61/333,750, filed on May 11, 2010, the contents of which are hereby incorporated by reference in their entirety into the present disclosure.
- The present disclosure relates generally to compositions and methods for cosmetic, medical and personal care.
- Throughout the disclosure, various technical and patent literature are identified by a bibliographic citation. The contents of all technical and patent literature are incorporated into the present disclosure by reference in their entirety.
- Film forming materials have broad use in therapeutic, cosmetic and personal care applications. Such materials are used to coat a body surface, such as skin, nail and hair, for the protection of the surface or to apply therapeutic or cosmetic ingredients to the surface.
- The film forming process typically involves a chemical reaction and solvent evaporation. The chemical reaction, such as polymerization of cyanoacrylate, can be quickly initiated by water or keratinous protein and forms a polymeric film on a surface. Alternatively, the chemical reaction may be epoxy-curing, UV or thermal polymerization of unsaturated monomers, radiation-induced curing or other ring-opening reactions.
- Solvent evaporation, on the other hand, can help form a uniform layer of film on the surface. Water is widely used as a non-toxic solvent or as a dispersing medium as in the cases for latex and dispersions. Alcoholic solvents are another group of solvents, although many film forming materials have limited or no solubility in these solvents. Other examples of organic solvents include alkyl acetate, acetone and toluene.
- Many film forming materials rely solely on the physical interactions between the material and the body surface to adhere to the surface. These interactions include van de Waals forces, dipolar interaction and hydrogen bonding. In general, these interactions are relatively weak, which often leads to poor adhesion to the skin and premature flake-off of the resultant film. Moreover, grease and sweat on the skin, for example, can further weaken the adhesion.
- There has been a long felt need for improved film forming compositions, which are simple to apply, can form a flexible film quickly and adhere strongly to a substrate. It is also preferred that the formed films are breathable and non-toxic.
- It is herein discovered, unexpectedly, that when polyvinyl acetal (PVA) is mixed with siloxane having a hydrophilic group, in a solvent, it constitutes a film forming composition suitable for medical and cosmetic uses. Thus, the present disclosure provides compositions, kits and methods of preparing a biocompatible film for cosmetic or medical uses. The compositions or kits contain polyvinyl acetal (PVA), siloxane and a solvent. Once the solvent content is reduced, for instance, by evaporation, the mixture of PVA and siloxane is solidified, forming a film. The compositions and kits, optionally, further include one or more of an antimicrobial agent, a pigment, an anti-inflammatory agent, an anesthetic agent or a hemostatic agent.
- Polyvinyl acetals have been used in the production of safety glass in automotive construction and for architectural uses. Plasticized polyvinyl butyral films, for example, are used as an intermediate layer in glazing units.
- For applications on human surface, however, PVA are not flexible enough and do not provide adequate adhesion to the surface. The inadequate adhesion is caused, in part, by the inherit brittleness of PVA. Thus, plasticizers and adhesion promoters are sometimes added to PVA to provide better adhesion. Such plasticizers and adhesion promoters, however, are either not suitable for human use. For example, certain such films show coloration due to yellowing of aminosilanes and their unpleasant odor and skin-irritant action, a known problem when using amino-functional compounds. When plasticizers are used to make the film flexible, it inevitably weakens adhesion between the film and skin, due to the lack of strong interactions with skin.
- The present discovery, however, shows that the combination of PVA and siloxane, in particular siloxane having a hydrophilic group, or alternatively a functional or a polar group, makes the composition not only adequately adhesive to a body surface, but also provides good flexibility and breathability, an obvious advantage for human use.
- It is further discovered that such compositions can also include therapeutic or cosmetic ingredients, enabling a broad range of applications in personal care. Such compositions can form a film that can be used, for example, in the form of an antimicrobial sealant, a liquid bandage, body paints, scar camouflage, water-proof sun block, makeup sealer, or antimicrobial wipe or spray.
- Accordingly, the present disclosure provides, in one embodiment, a composition comprising polyvinyl acetal (PVA) and siloxane, wherein the siloxane comprises a hydrophilic group. Alternatively, the siloxane comprises a functional group or a polar group. In some aspects, the composition further comprises a solvent.
- In one aspect, the hydrophilic group comprises one or more of the group of a halogen, oxygen, nitrogen, sulfur or phosphorus. In another aspect, the hydrophilic group is one or more of the group of a carboxylic acid, an amino group, a hydroxyl group, an epoxy group or an anhydride group.
- Examples of the hydrophilic group include, without limitation,
- (3-glycidoxypropyl)dimethylethoxysilane,
- (3-glycidoxypropyl)pentamethyldisiloxane,
- (3-glycidoxypropyl)methyldiethoxysilane,
- (3-glycidoxypropyl)triethoxysilane,
- 5,6-epoxyhexyltriethoxysilane,
- (3-glycidoxypropyl)bis(trimethylsiloxy)methylsilane,
- 1,3-bis(glycidoxypropyl)tetramethyldisiloxane,
- 1,5-bis(glycidoxypropyl)-3-phenyl-1,1,3,5,5-pentamethyltrisiloxane,
- bis[2-(3,4-epoxycyclohexyl)ethyl]tetramethyldisiloxane,
- mono-(2,3-epoxy)propylether terminated polydimethylsiloxane,
- epoxypropoxypropyl terminated polydimethylsiloxane,
- epoxycyclohexylethyl terminated polydimethylsiloxane,
- epoxypropylheptaisobutyl-T8-silsesquioxane,
- succinic anhydride terminated polydimethylsiloxane,
- bis(2-hydroxyethyl)-3-aminopropyltriethoxysilane,
- 1,3-bis(hydroxypropyl)tetramethyldisiloxane,
- 1,3-bis(hydroxybutyl)tetramethyldisiloxane,
- monocarbinol terminated polydimethylsiloxane,
- 3-[hydroxy(polyethyleneoxy)propyl]heptamethyltrisiloxane,
- trimethylsilylpropionic acid,
- 1,3-bis(3-carboxypropyl)tetramethyldisiloxane, or
- 3-(triethoxysilyl)propylsuccinic anhydride.
- In some aspects, the siloxane has a structure of:
- wherein:
-
- X is selected from the group consisting of an amino group, an epoxy group, a hydroxyl group, a carboxylic acid group, and a maleic anhydride group;
- R1 is a divalent organic group optionally substituted with an oxygen, nitrogen, or sulfur atom, or is selected from the group consisting of a substituted or non-substituted C2-C20-aliphatic group, a substituted or non-substituted aromatic group, and a substituted or non-substituted aliphatic aromatic group;
- R2 and R3 are independently selected from the group consisting of a lower alkyl group, a lower alkoxy group, and a polymeric siloxane group;
- R4 is selected from the group consisting of a lower alkyl group, an oligomeric or a polymeric siloxane group and
- In one aspect, the PVA has a molecular weight from about 25,000 to about 250,000, or alternatively from about 50,000 to about 200,000, or alternatively from about 75,000 to about 175000, or alternatively from about 100,000 to about 150,000.
- In another aspect, the PVA has a degree of polymerization of from about 200 to about 2,000, or alternatively from about 300 to about 1500, or alternatively from about 400 to about 1200, or alternatively from about 400 to about 800.
- In some aspects, the PVA has a degree of hydrolysis greater than about 70 mol %, or alternatively about 80 mol %, or about 85 mol %, or about 90 mo %, or about 95 mol %, or about 98 mol %, or about 99 mol %.
- In still some aspects, the PVA has a structure of:
- wherein R is selected from the group of methyl, ethyl, propyl, butyl, hexyl or benzyl, A is an integer in the range of from about 50 to about 1800, B is an integer in the range of from about 10 to about 800 and C is an integer from the range of from about 0 to about 1000.
- In a particular aspect, the PVA comprises polyvinyl butyral (PVB). In one embodiment, the PVB constitutes about 70% to about 90% by weight of the PVA.
- Still in another aspect, the PVA has a concentration of from about 0.1 wt/vol % to about 60 wt/vol % in the composition, or alternatively from about 1 wt/vol % to about 30 wt/vol % in the composition, or alternatively from about 2 wt/vol % to about 25 wt/vol % in the composition, or alternatively from about 5 wt/vol % to about 20 wt/vol % in the composition, or alternatively from about 10 wt/vol % to about 15 wt/vol % in the composition.
- The solvent in the composition can be an inorganic solvent or an organic solvent. Non-limiting examples of inorganic solvent include water, saline or combinations thereof. Non-limiting examples of organic solvent includes one or more of the group of methanol, ethanol, isopropanol, n-propanol, butanol, methyl cellosolve, butyl cellosolve, methyl acetate, ethyl acetate, isopropyl acetate, butyl acetate, acetone, methyl ethyl ketone, toluene, xylene, dichloromethane or chloroform.
- In another embodiment, the composition further comprises an antimicrobial agent. The antimicrobial agent can be one or more of the group of silver compounds, quaternary ammonium cations, or acid-anionic surfactants.
- In yet another embodiment, the composition further comprises a pigment, such as, but not limited to, iron oxides, titanium dioxides, extender pigments ultramarine pigments, manganese violet, mixed metal oxide pigments, fluorescent pigments, carbon black, magnetite, lodestone, or magnetic iron oxide.
- Still in another embodiment, the composition further comprises an anti-inflammatory agent. Examples of anti-inflammatory agent include, without limitation, ibuprofen, naproxen sodium, aspirin, ketoprofen, procaine, cocaine, lidocaine, priocaine, bupivacaine, levobupivacaine, ropivacaine or dibucaine.
- Yet another embodiment provides a composition that further comprises an anesthetic agent. In one aspect, the anesthetic agent is one or more of the group of lidocaine, prilocalne, bupivicaine, levobupivacaine, ropivacaine, mepivacaine or dibucaine.
- Also provided, in still another embodiment, is a composition further comprising a hemostatic agent. In some aspects, the hemostatic agent is one or more of the group of oxidized regenerated cellulose, gelatin, fibrin, thrombin, alginate, zeolite, collagen or chitosan.
- The composition of any of the above embodiment can be provided in a solid, gel or liquid form, can be prepared in a form that is pharmaceutically acceptable.
- In one embodiment, the present disclosure provides a composition prepared by admixing PVA and siloxane in a solvent, wherein the siloxane comprises a hydrophilic group. Examples of PVA, siloxane, solvent and hydrophilic group are provided above and generally in the disclosure.
- Also provided, in one embodiment, is a film that is obtained by reducing the content of the solvent in a composition of any of the above embodiments, or a film that is obtainable by reducing the content of the solvent in a composition of any of the above embodiments. In one aspect, the solvent is reduced by evaporation.
- Kits are also provided, comprising, in two or more separate compartments, polyvinyl acetal (PVA), siloxane and a solvent. In some aspects, the kit further comprises one or more of an antimicrobial agent, a pigment, an anti-inflammatory agent, an anesthetic agent or a hemostatic agent.
- The present disclosure also provides, in one embodiment, a method of preparing a film on a skin, comprising applying a suitable amount of a composition of any of the above embodiments on the skin and allowing the solvent to evaporate.
- Further provided is a method of preparing an antimicrobial sealant on a skin, comprising applying a suitable amount of a composition of the present disclosure on the skin and allowing the solvent to evaporate.
- Still provided, in one embodiment, is a method of preparing a body paint on a skin, comprising applying a suitable amount of a composition of the present disclosure on the skin and allowing the solvent to evaporate
- As used herein, certain terms may have the following defined meanings. As used in the specification and claims, the singular form “a,” “an” and “the” include singular and plural references unless the context clearly dictates otherwise. For example, the term “a film” includes a single film as well as a plurality of films, including mixtures thereof.
- As used herein, the term “comprising” is intended to mean that the compositions and methods include the recited elements, but not excluding others. “Consisting essentially of” when used to define compositions and methods, shall mean excluding other elements of any essential significance to the composition or method. “Consisting of” shall mean excluding more than trace elements of other ingredients for claimed compositions and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention. Accordingly, it is intended that the methods and compositions can include additional steps and components (comprising) or alternatively including steps and compositions of no significance (consisting essentially of) or alternatively, intending only the stated method steps or compositions (consisting of).
- All numerical designations, e.g., pH, temperature, time, concentration, and molecular weight, including ranges, are approximations which are varied (+) or (−) by increments of 0.1. It is to be understood, although not always explicitly stated that all numerical designations are preceded by the term “about”. The term “about” also includes the exact value “X” in addition to minor increments of “X” such as “X+0.1” or “X−0.1.” It also is to be understood, although not always explicitly stated, that the reagents described herein are merely exemplary and that equivalents of such are known in the art.
- It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present specification. In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings:
- “Aromatic” indicates that each of ring atoms is essentially in the same plane and has a p-orbital perpendicular to the ring plane, and in which (4n+2) m electrons, when n is 0 or a positive integer, are associated with the ring to comply with Huckel's rule. Aromatic ring systems may be depicted as a circle, which represents the (4n+2) m electrons, enclosed by an outer cyclic structure, such as, a hexagon or pentagon. For example, each of the rings in the compound of Formula I is aromatic.
- “Alkyl” refers to monovalent saturated aliphatic hydrocarbyl groups having from 1 to 10 carbon atoms and, in some embodiments, from 1 to 6 carbon atoms. “Cx-yalkyl” refers to alkyl groups having from x to y carbon atoms. This term includes, by way of example, linear and branched hydrocarbyl groups such as methyl (CH3—), ethyl (CH3CH2—), n-propyl (CH3CH2CH2—), isopropyl ((CH3)2CH—), n-butyl (CH3CH2CH2CH2—), isobutyl ((CH3)2CHCH2—), sec-butyl ((CH3)(CH3CH2)CH—), t-butyl ((CH3)3C—), n-pentyl (CH3CH2CH2CH2CH2—), and neopentyl ((CH3)3CCH2—).
- “Lower alkyl” refers to an alkyl with from 1 to 6 carbon atoms.
- “Alkoxy” refers to the group —O-alkyl wherein alkyl is defined herein. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy, and n-pentoxy.
- “Lower alkoxy” refers to an alkoxy with from 1 to 6 carbon atoms.
- “Amino” refers to the group —NH2.
- “Hydroxyamino” refers to the group —NHOH.
- “Alkoxyamino” refers to the group —NHO-alkyl wherein alkyl is defined herein.
- “Cyano” or “carbonitrile” refers to the group —CN.
- “Epoxy” refers to a group continaing an oxygen atom joined by single bonds to two adjacent carbon atoms, thus forming the three-membered epoxide ring.
- “Anhydride” refers to a group having two acyl groups bound to the same oxygen atom. “Maliec anhydride” refers to the acid anhydride group of malice acid.
- “Carboxyl”, “carboxy” or “carboxylic acid” refers to —COOH or salts thereof.
- The term “halogen” or “halo” refers to fluoro, bromo, chloro, and iodo.
- “Hydroxy” or “hydroxyl” refers to the group —OH.
- “Nitro” refers to the group —NO2.
- “Thiol” refers to the group —SH.
- “Compound” and “compounds” as used herein refers to a compound encompassed by the generic formulae disclosed herein, any subgenus of those generic formulae, and any forms of the compounds within the generic and subgeneric formulae, including the racemates, stereoisomers, and tautomers of the compound or compounds.
- “Stereoisomer” or “stereoisomers” refer to compounds that differ in the chirality of one or more stereocenters. Stereoisomers include enantiomers and diastereomers.
- “Tautomer” refer to alternate forms of a compound that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or the tautomeric forms of heteroaryl groups containing a ring atom attached to both a ring —NH— moiety and a ring ═N— moiety such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles.
- Unless indicated otherwise, the nomenclature of substituents that are not explicitly defined herein are arrived at by naming the terminal portion of the functionality followed by the adjacent functionality toward the point of attachment. For example, the substituent “arylalkyloxycabonyl” refers to the group (aryl)-(alkyl)-O—C(O)—.
- It is understood that in all substituted groups defined above, polymers arrived at by defining substituents with further substituents to themselves (e.g., substituted aryl having a substituted aryl group as a substituent which is itself substituted with a substituted aryl group, which is further substituted by a substituted aryl group etc.) are not intended for inclusion herein. In such cases, the maximum number of such substitutions is three. For example, serial substitutions of substituted aryl groups with two other substituted aryl groups are limited to -substituted aryl-(substituted aryl)-substituted aryl.
- Similarly, it is understood that the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluoro groups). Such impermissible substitution patterns are well known to the skilled artisan.
- A “hydrophilic group” refers to a group that is attracted to, and tends to be dissolved by water. A hydrophilic group has a tendency to interact with or be dissolved by water and other polar substances. In one aspect, a hydrophilic group is charge-polarized and capable of hydrogen bonding, enabling it to dissolve more readily in water than in oil or other hydrophobic solvents. Hydrophilic and hydrophobic molecules are also known as polar molecules and nonpolar molecules, respectively.
- A “polar group” refers to a chemical group in which the distribution of electrons is uneven enabling it to take part in electrostatic interactions.
- “Polymerization initiator” refers to an agent that promotes initiation of a polymerization reaction. A polymerization initiator, in one aspect, reacts with a monomer to form an intermediate compound capable of linking successively with a large number of other monomers into a polymeric compound. One type of initiators produce free radicals, such as peroxides and aliphatic azo compounds used to polymerize vinyl chloride, methyl methacrylate, and other monomers. In one aspect, a polymerization initiator is an anion. In another aspect, a polymerization initiator is a photoactive initiator, such as but not limited to alpha hydroxyketone, like Irgacure 184, Irgacure 2959 or DAROCUR®1173 from Ciba Specialty Chemicals Inc.
- “Degree of polymerization” or “DP” refers to the number of monomeric units in a macromolecule or polymer or oligomer molecule. For a homopolymer, there is only one type of monomeric unit and the number-average degree of polymerization is given by total molecular weight divided by molecular weight of the monomer unit. For a copolymer, DP refers to the number of repeat units.
- “Degree of hydrolysis” refers to the fraction of a compound, which has undergone hydrolysis at equilibrium. Hydrolysis is a chemical reaction of one compound with water, often resulting in the formation of one or more new compounds. For polyvinyl acetal, degree of hydrolysis is the percentage of dangling acetate on the polymer backbone, which has hydrolyzed to form dangling hydroxyl groups and free acetate.
- “Degree of acetalization” refers to the molar percentage of hydroxyl group substitution via acetalization with aldehyde during the synthesis of polyvinyl acetal.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
- The present disclosure provides film forming compositions. The compositions can be non-toxic, coatable and sprayable. After application, the compositions can form flexible films quickly. The film can chemically react with skin, adhere to skin for prolonged time of period. Another advantage is that the composition can accommodate active ingredients, such as drugs, pigments, inorganic particles and antimicrobial agents for killing bacteria and viruses.
- In one embodiment, the present disclosure provides, in one embodiment, a composition comprising, or alternatively consisting essentially of, or alternatively consisting of, polyvinyl acetal (PVA) and siloxane, wherein the siloxane comprises a hydrophilic group. Alternatively, the siloxane comprises a functional group or a polar group. In some aspects, the composition further comprises a solvent.
- PVA demonstrates outstanding adhesion to many surfaces, is compatible with active ingredients, chemically and thermally stable and non-toxic. PVA can form flexible and water-repellent films. It is also noted that PVA has good solubility in alcohol and lower alkyl acetate.
- PVA has long polymer chains, contributing to toughness combined with flexibility of the film. Along the long polymer chains, there are randomly distributed hydroxyl groups, acetate groups, and acetals, contributing to the outstanding binding efficiency and adhesion to a large number of surfaces because the hydroxyl groups, acetate groups and acetals interact with different groups on the surface for strong binding. The random distribution of the groups on the polymer chains minimizes the probability of crystallization, which in turn results in excellent optical clarity of the formed film. PVA films are characterized by high resistance to aliphatic hydrocarbons, mineral, animal and vegetable oils (with the exception of castor and blown oils).
- Acetals offer stability against all types of nucleophiles and bases and most oxidants, so long as the conditions do not lead to hydrolysis of the acetal. Additionally, acetals withstand strong alkalis but are subject to some attack by strong acids. The stability of PVA film contributes to the compatibility with other active ingredients. For example, when ethanol is as the solvent, the film forms quickly in a matter of seconds via ethanol evaporation.
- In the current technology, siloxane, as a plasticizer, is introduced to make the film flexible and to increase the gas permeability of the resultant film, making the film breathable. This feature will ultimately bring comfort to consumer.
- One unexpected finding of the present disclosure is based on the conventional wisdom that siloxane is inherently inert and shows poor adhesion to most surfaces. It is therefore widely perceived that siloxane does not serve as a good plasticizer for a film forming composition, which forms films that need to adhere to a surface. This is because the introduction of siloxane would undoubtedly result in weakened adhesion of the resultant film to the surface.
- In the present technology, such negative effect of siloxane is eliminated by including one or more polar groups or alternatively hydrophilic groups into the siloxane. Such polar or hydrophilic groups help form either chemical bonds or strong electrostatic interactions with the surface such as skin. Chemical bonds are much stronger than physical interactions and thus can greatly enhance the adhesion. In this context, siloxane with polar or hydrophilic groups such as epoxy and maleic anhydride can be used as both a plasticizer and adhesion promoter.
- It is further contemplated that, in one embodiment of the present disclosure, there is an absence of polymerization initiator in the film forming composition. Conventional film forming formulation of cyanoacrylate requires the presence of anions as initiators for starting the reaction in situ. In another aspect, a polymerization initiator is a chemical that generate free radicals, such as peroxides and aliphatic azo compounds. UV curing formulations usually need photoactive initiators to generate the first batch of free radicals under UV lights for subsequent polymerization. These UV initiators include alpha hydroxyketone, like Irgacure 184, Irgacure 2959 and DAROCUR®1173 from Ciba Specialty Chemicals Inc. In the present technology, no polymerization initiator is required for the formation of a flexible, breathable, durable and waterproof on skin. Associated with feature, another advantage of the present technology is apparent, that is, the absence of initiators and low molar mass olefinic monomers in the technology minimizes film toxicity due to residual initiator or monomers.
- Mammalian skin is composed of three primary layers: a. the epidermis, which provides waterproofing and serves as a barrier to infection; b. the dermis, which serves as a location for the appendages of skin; c. the hypodermis (subcutaneous adipose layer). Epidermis is the outermost layer of the skin. It forms the waterproof, protective wrap over the body's surface and is made up of stratified squamous epithelium with an underlying basal lamina. The epidermis can be further subdivided into the following strata (beginning with the outermost layer): corneum, lucidum (only in palms of hands and bottoms of feet), granulosum, spinosum, basale. Cells are formed through mitosis at the basale layer. The daughter cells move up the strata changing shape and composition as they die due to isolation from their blood source. The cytoplasm is released and the protein keratin is inserted. They eventually reach the corneum and slough off. This process is called keratinization and takes place within about 27 days.
- It is keratinization and the inert nature of keratin that make it difficult for film-forming compositions to adhere to the skin for a prolonged period of time. According to Wilkerson (Journal of Biological Chemistry, 107, 377, 1934), the stratum corneum has the following composition: cystine, 2.34%; tyrosine, 5.70%; histidine, 0.59%; lysine 3.08%; arginine, 10.01%. The primary amino group from lysine has great reactivity with epoxy and maleic anhydride under ambient conditions. Thus, lysine, for instance, from the skin, can be employed to react with siloxane having the corresponding reactive or functional group which is polar or hydrophilic, for greatly enhanced adhesion.
- Methods of preparing polyvinyl acetals (PVA) are well known in the art. For instance, PVA can be prepared from aldehydes and polyvinyl alcohols. Acetals are formed by the well-known reaction between aldehydes and alcohols. The addition of one molecule of an alcohol to one molecule of an aldehyde produces a hemiacetal. Hemiacetals are rarely isolated because of their inherent instability, but, rather, are further reacted with another molecule of alcohol to form a stable acetal.
- Polyvinyl alcohols are high molecular weight resins containing various percentages of hydroxyl and acetate groups produced by hydrolysis of polyvinyl acetate. The conditions of the acetal reaction and the concentration of the particular aldehyde and polyvinyl alcohol used are closely controlled to form polymers containing predetermined proportions of hydroxyl groups, acetate groups and acetal groups. The final product may be represented by the following stylized structure. The proportions of A, B and C are controlled, and they are randomly distributed along the molecule.
- Here R can be methyl, ethyl, propyl, butyl, hexyl, benzyl group and combinations thereof. A can be an integer in the range of from about 50 to about 1800, or from 100 to about 1000; B can be an integer in the range of from about 10 to about 800, or from about 100 to about 500; and C can be an integer from the range of 0 to about 1000, or from about 100 to about 500.
- In one aspect, the polyvinyl alcohol has a molecular weight from about 25,000 to about 250,000, or alternatively from about 50,000 to about 200,000, or alternatively from about 75,000 to about 175000, or alternatively from about 100,000 to about 150,000.
- In another aspect, the polyvinyl alcohol has a degree of polymerization of from about 200 to about 2,000, or alternatively from about 300 to about 1500, or alternatively from about 400 to about 1200, or alternatively from about 400 to about 800.
- In some aspects, the polyvinyl alcohol has a degree of hydrolysis greater than about 70 mol %, or alternatively about 80 mol %, or about 85 mol %, or about 90 mol %, or about 95 mol %, or about 98 mol %, or about 99 mol %. In some aspects, the polyvinyl alcohol has a degree of hydrolysis that is lower than about 99.99 mol %, or alternatively lower than about 99.9 mol %, or alternatively lower than about 99 mol %, or alternatively lower than about 98 or 95 mol %. It is noted that when the degree of hydrolysis is too low, the solubility in water is low and polyvinyl alcohol is difficult to produce from it. On the other hand, polyvinyl alcohol having a too high degree of hydrolysis is difficult to produce.
- Polyvinyl alcohol can be acetalized into polyvinyl acetal under an acidic condition in an aqueous solvent according to a known method. The polyvinyl acetal thus obtained herein, in one aspect, has a degree of acetalization of from about 45 to about 90 mol %. Alternatively, the degree of acetalization is from about 50 to about 85 mol %, or from about 55 to about 80 mol %, or from about 60 to about 75 mol %. Polyvinyl alcohol with too low a degree of acetalization is unfavorable since the powdery reaction product obtained through acetalization can be difficult to recover and since the waterproofness of the polyvinyl acetal obtained can be low or the compatibility of polyvinyl acetal with plasticizer can be low. When the degree of acetalization of polyvinyl acetal is too high, the polyvinyl acetal of the type can be difficult to produce, and its compatibility with plasticizer may be lowered.
- The aldehyde compound to be used for the acetalization includes, for example, formaldehyde, acetaldehyde, propionaldehyde, butylaldehyde, hexylaldehyde and benzaldehyde. These may be used singly or as a mixture of two or more of them. In some aspects, the aldehyde compounds are alkyaldehyde having at most four carbon atoms and benzaldehyde and butylaldehyde are preferred.
- There are commercially available polyvinyl acetal resins, like polyvinyl formal acetal and polyvinyl butyral. For example, polyvinyl butyral resins are sold by Solutia under the name of Butvar®, and by Kuraray under the name of Mowital®. Butvar® B-72, B-74, B-76, B-79, B-90, and B-98 are polyvinyl butyrals with molecular weights between 40 and 250 kg/mol, butyral content expressed as % polyvinyl butyral between 80 and 88%; acetate content expressed as % polyvinyl acetate between 0.0 and 2.5%; hydroxyl content expressed as % polyvinyl alcohol between 11.5 and 20%. Mowital® B20H, B30T, B30H, B30HH, B45H, B60T, B60H, B60HH, and B75H have molecular weights from 20 to 100 kg/mol.
- A particular example of PVA is polyvinyl butyral (PVB). In one aspect, a polyvinyl butyral content of between about 70 and about 90% weight of the total polymer is used. Alternatively, the content is from about 72 to about 85%, or from about 73 to about 80%, or about 75%.
- Examples of polyvinyl butyrals resins and properties of such resins are disclosed in the brochures provided by Solutia Inc. and Kuraray America Inc. These PVB polymers can be used singly or mixed with one or more other grades. Exemplary polyvinyl butyrals are Butvar® B-72, Butvar® B-74, Butvar® B-76, Butvar® B-79 and Butvar® B-98. The content of PVB is preferably within a range of 0.1 wt/vol % to 60 wt/vol % based on the solvent, and more preferably within a range of 1-30 wt/vol % in view of the resultant film flexibility and adhesion to skin.
- A siloxane is any chemical compound composed of units of the form R2SiO, where R is a hydrogen atom or a hydrocarbon group, as well as their derivatives. Siloxanes can have branched or unbranched backbones consisting of alternating silicon and oxygen atoms —Si—O—Si—O—, with side chains R attached to the silicon atoms.
- In some aspects, the siloxane has a structure of:
- wherein:
-
- X is selected from the group consisting of an amino group, an epoxy group, a hydroxyl group, a carboxylic acid group, and a maleic anhydride group;
- R1 is a divalent organic group optionally substituted with an oxygen, nitrogen, or sulfur atom, or is selected from the group consisting of a substituted or non-substituted C2-C20-aliphatic group, a substituted or non-substituted aromatic group, and a substituted or non-substituted aliphatic aromatic group;
- R2 and R3 are independently selected from the group consisting of a lower alkyl group, a lower alkoxy group, and a polymeric siloxane group;
- R4 is selected from the group consisting of a lower alkyl group, an oligomeric or a polymeric siloxane group and
- In one aspect, X is selected from the group consisting of an amino group, an epoxy group, a hydroxyl group, a carboxylic acid group, and a maleic anhydride group. In another aspect, R1 is a divalent organic group optionally substituted with an oxygen, nitrogen, or sulfur atom, or is selected from the group consisting of a substituted or non-substituted C2-C20-aliphatic group, a substituted or non-substituted aromatic group, and a substituted or non-substituted aliphatic aromatic group. In yet another aspect, R2 is selected from the group consisting of a lower alkyl group, a lower alkoxy group, and a polymeric siloxane group. In still another aspect, R3 is selected from the group consisting of a lower alkyl group, a lower alkoxy group, and a polymeric siloxane group. In another aspect, R4 is selected from the group consisting of a lower alkyl group, an oligomeric or a polymeric siloxane group and
- In one aspect, the hydrophilic group comprises one or more of the group of halogen, oxygen, nitrogen, sulfur or phosphorus. In another aspect, the hydrophilic group is one or more of the group of a carboxylic acid, an amino group, a hydroxyl group, an epoxy group or an anhydride group.
- Examples of the hydrophilic group include, without limitation,
- (3-glycidoxypropyl)dimethylethoxysilane,
- (3-glycidoxypropyl)pentamethyldisiloxane,
- (3-glycidoxypropyl)methyldiethoxysilane,
- (3-glycidoxypropyl)triethoxysilane,
- 5,6-epoxyhexyltriethoxysilane,
- (3-glycidoxypropyl)bis(trimethylsiloxy)methylsilane,
- 1,3-bis(glycidoxypropyl)tetramethyldisiloxane,
- 1,5-bis(glycidoxypropyl)-3-phenyl-1,1,3,5,5-pentamethyltrisiloxane,
- bis[2-(3,4-epoxycyclohexyl)ethyl]tetramethyldisiloxane,
- mono-(2,3-epoxy)propylether terminated polydimethylsiloxane,
- epoxypropoxypropyl terminated polydimethylsiloxane,
- epoxycyclohexylethyl terminated polydimethylsiloxane,
- epoxypropylheptaisobutyl-T8-silsesquioxane,
- succinic anhydride terminated polydimethylsiloxane,
- bis(2-hydroxyethyl)-3-aminopropyltriethoxysilane,
- 1,3-bis(hydroxypropyl)tetramethyldisiloxane,
- 1,3-bis(hydroxybutyl)tetramethyldisiloxane,
- monocarbinol terminated polydimethylsiloxane,
- 3-[hydroxy(polyethyleneoxy)propyl]heptamethyltrisiloxane,
- trimethylsilylpropionic acid,
- 1,3-bis(3-carboxypropyl)tetramethyldisiloxane, or
- 3-(triethoxysilyl)propylsuccinic anhydride.
- Siloxanes are commercially available from various vendors.
- The content of silanol groups in the siloxane after modification is preferably within a range of from 0.1 wt. % to 60 wt. % based on the resin so modified, and more preferably within a range of 3-40 wt. % in view of the processability and adhesion.
- The solvent in the disclosed compositions can be inorganic or organic. Examples of the organic solvent include, without limitation, alcohols such as methanol, ethanol, isopropanol, n-propanol, butanol; cellosolves such as methyl cellosolve, butyl cellosolve; ketones such as acetone, methyl ethyl ketone; aromatic hydrocarbons such as toluene, xylene; and halohydrocarbons such as dichloromethane, chloroform; alkyl acetate, such as methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate, amyl acetate, isoamyl acetate, heptyl acetate, octyl acetate, nonanyl acetate, decyl acetate; aromatic acetate, such as benzyl acetate. One or more of these may be used herein either singly or as combined. Among these solvents, ethanol is more preferred. Other examples include methanol, ethanol, isopropanol, n-propanol, butanol, methyl cellosolve, butyl cellosolve, alkyl acetate, acetone, methyl ethyl ketone, toluene, xylene, dichloromethane or chloroform.
- Non-limiting examples of inorganic solvent include water, saline or combinations thereof.
- In some embodiments, the composition can contain any known ordinary additives such as UV absorbent, light stabilizer, antioxidant, surfactant, or colorant.
- Traditional plasticizers for polyvinyl acetals are tri or tetraethylene glycol dicarboxylates such as triethylene glycol di-2-ethylhexanoate, tetraethylene glycol di-2-ethylhexanoate, triethylene glycol di-n-heptanoate, tetraethylene glycol di-n-deptanoate; and dicarboxylates such as dioctyl adipate, dibutyl adipate, dioctyl phthalate and dibutyl phthalate. One or more of these may be used herein either singly or as combined.
- Antimicrobial agents are chemical compounds that destroy microbes, prevent their pathogenic action, or prevent their growth. Antimicrobial agents, often referred to as anti-infective agents, are frequently applied topically to the skin and mucous membranes in the form of a solution, cream, or ointment; appropriate formulations may be applied to wound and body cavities, and to the eyes, nose and mouth.
- Examples of antimicrobial agents include, without limitation, silver particles, silver compounds like silver chloride, silver acetate, silver oxide, silver sulfate, silver nitrate, silver thiosulfate and combinations thereof. The antimicrobial activity of inorganic substances is generally related to the ions into which they dissociate. The antimicrobial activity of various metal ions, for example, is often attributed to their affinity for protein material and the insolubility of the metal proteinate formed.
- Quaternary ammonium cations, also known as quats, another type of antimicrobial agent, are positively charged polyatomic ions of the structure NR4 +, R being an alkyl group. Unlike the ammonium ion (NH4 +) and the primary, secondary, or tertiary ammonium cations, the quaternary ammonium cations are permanently charged, independent of the PH of their solution. Quaternary salts are another type of antimicrobial agents, with a general structure shown below:
- where A1, A2, A3 and A4 can each be, independent of one another, hydrogen, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above. Also, any of the A1, A2, A3 and A4 substituents can be absent and any of the remaining substituents can be a multivalent group. Certain quaternary ammonium compounds, especially those containing long alkyl chains, are used as antimicrobials and disinfectants. Examples are benzalkonium chloride, benzethonium chloride, methylbenzethonium chloride, cetalkonium chloride, cetylpyridinium chloride, cetrimonium, cetrimide, dofanium chloride, tetraethylammonium bromide, didecyldimethylammonium chloride and domiphen bromide. Also good against fungi, amoeba, and enveloped viruses, quats act by disrupting the cell membrane. Quaternary ammonium compounds are lethal to a wide variety of organisms except endospores, Mycobacterium tuberculosis, non-enveloped viruses, and Pseudomonas spp.
- The use of acid-anionic surfactants as antibacterial agents is also known. Suitable surfactants may include sodium lauryl sulfate, linear alkylbenzene sulfonates, alcohol sulfates, alkyl sulfates, alkyl sulfonates, sodium alkyl methyltaurines, alpha-olefin sulfonates, alcohol ethoxylates, nonylphenyl ethoxylates, alkylpolyglucosides, fatty alcohols, fatty acids and fatty acid salts, lignosulfonates and lignin derivatives, hydroxypoly(oxyethylene) derivatives, fatty alkanolamides, fatty amine oxides, sodium dioctylsulfosuccinate, dodecylbenzene sulfonic acid and salts thereof, the sodium salt of sulfonated oleic acid, sodium dodecylbenzene sulfonate, lauramine oxide, dodecyldiphenyloxide-disulfonic acid and salts thereof.
- Further examples of surfactants include alkyl(C8-C24) benzenesulfonic acid and its ammonium, calcium, magnesium, potassium, sodium, and zinc salts; alkyl(C8-C18) sulfate and its ammonium, calcium, isopropylamine, magnesium, potassium, sodium, and zinc salts; diethylene glycol abietate, lauryl alcohol, lignosulfonate and its ammonium, calcium, magnesium, potassium, sodium, and zinc salts; nonyl, decyl, and undecyl glycoside mixture with a mixture of nonyl, decyl, and undecyl oligosaccharides and related reaction products (primarily decanol and undecanol) produced as an aqueous based liquid (50 to 65% solids) from the reaction of primary alcohols (containing 15 to 20% secondary alcohol isomers) in a ratio of 20% C9, 40% C10, and 40% C11 with carbohydrates (average glucose to alkyl chain ratio 1.3 to 1.8); alpha-(o,p-dinonylphenyl)-omega-hydroxypoly (oxyethylene) mixture of dihydrogen phosphate and monohydrogen phosphate esters and the corresponding ammonium, calcium, magnesium, monethanolamine, potassium, sodium, and zinc salts of the phosphate esters; the poly (oxyethylene) content averages 4-14 moles; alpha-(p-nonylphenyl)-.omega.-hydroxypoly (oxyethylene) mixture of dihydrogen phosphate and monohydrogen phosphate esters and the corresponding ammonium, calcium, magnesium, monethanolamine, potassium, sodium, and zinc salts of the phosphate esters, the poly(oxyethylene) content averages 4-14 moles or 30 moles; .alpha.-(p-nonylphenyl)-.omega.-hydroxypoly (oxyethylene) produced by the condensation of 1 mole nonylphenol with an average of 4-14 moles or 30-90 moles ethylene oxide; .alpha.-(p-nonylphenyl)-.omega.-hydroxypoly (oxyethylene) sulfate, ammonium, calcium, magnesium, potassium, sodium, and zinc salts; octyl and decyl glucosides mixture with a mixture of octyl and decyloligosaccharides and related reaction products (primarily n-decanol) produced as an aqueous based liquid (68-72% solids) from the reactions of straight chain alcohols (C8 (45%), C10 (55%)) with anhydrous glucose; oxidized pine lignin and its salts thereof; beta-pinene polymers; polyethylene glycol .alpha.-hydro-.omega.-hydroxypoly(oxyethylene)); mean molecular weight of 194 to 9500 amu; .alpha.-(p-tert-Butylphenyl)-.omega.-hydroxypoly (oxyethylene) mixture of dihydrogen phosphate and monohydrogen phosphate esters and the corresponding ammonium, calcium, magnesium, monethanolamine, potassium, sodium, and zinc salts of the phosphate esters; the poly (oxyethylene) content averages 4-12 moles; .alpha.-(o,p-dinonylphenyl)-omega-hydroxypoly (oxyethylene) produced by the condensation of 1 mole of dinonylphenol with an average of 4-14 or 140-160 moles of ethylene oxide; sodium or potassium salts of fatty acids; sodium .alpha.-olefinsulfonate (sodium C14-C16) (Olefin sulfonate); sodium diisobutylnaphthalene sulfonate and/or sodium isopropylisohexylnaphthalene sulfonate; sodium dodecylphenoxybenzenedisulfonate; sodium lauryl glyceryl ether sulfonate; sodium ° leyl sulfate; sodium N-lauroyl-N-methyltaurine, sodium N-palmitoyl-N-methyltaurine and/or sodium N-oleoyl-N-methyltaurine; sodium monoalkyl and dialkyl (C8-C16) phenoxybenzenedisulfonate mixtures containing not less than 70% of the monoalkylated products; 2,4,7,9-tetramethyl-5-decyn-4,7-diol; and/or nonylphenol ethoxylates with average moles of ethoxylation between 4 and 30.
- Further, in other embodiments the surfactant may be one or more of the following alcohol ethoxylates: alpha-Alkyl(C9-C18-omega-hydroxypoly(oxyethylene) with polyoxyethylene content of 2-30 moles; .alpha.-(p-alkylphenyl)-omega.-hydroxypoly(oxyethylene) produced by the condensation of 1 mole of alkylphenol (alkyl is a mixture of propylene tetramer and pentamer isomers and averages C13) with 6 moles ethylene oxide; .alpha.-Alkyl(C6-C14-.omega.-hydroxypoly(oxypropyylene) block copolymer with polyoxyethylene; polyoxypropylene content is 1-3 moles; polyoxyethylene content is 4-12 moles; average molecular weight is approximately 635 amu; .alpha.-Alkyl (C12-C15-.omega.-hydroxypoly(oxypropyylene)poly (oxyethylene) copolymers (where the poly(oxypropylene) content is 3-60 moles and the poly (oxyethylene) content is 5-80 moles; alpha-(p-Dodecylphenyl)-.omega.-hydroxypoly(oxyethylene) produced by the condensation of 1 mole of dodecylphenol with an average of 4-14 or 30-70 moles ethylene oxide; ethylene oxide adducts of 2,4,7,9-tetramethyl-5-decynediol, the ethyelene oxide content averages 3.5, 10, or 30 moles; alpha-Laurykomega.-hydroxypoly(oxyethylene), sodium salt; the poly(oxyethylene) content is 3-4 moles; secondary alkyl (C11-C15) poly(oxyethylene) acetate salts; ethylene oxide content averages 5 moles; alpha.4p-1,1,3,3-tetramethylbutyl)phenyl+.omega.-hydroxypoly(oxyethyl-ene) produced by the condensation of 1 mole of p-1,1,3,3-tetramethylbutylphenol with a range of 1-14 or 30-70 moles ethylene oxide; tridecylpoly(oxyethylene) acetate salts where the ethylene oxide content averages 6-7 moles; poly(oxy-1,2-ethanediyl), .alpha.-(carboxymethyl)-.omega.-(nonylphenoxy) produced by the condensation o 1 mole nonylphenol with an average of 4-14 or 30-90 moles ethylene oxide with a molecular weight in the ranges 454-894 and 1598-4238; and/or .alpha.-Stearoyl-.omega.-hydroxy(polyoxyethylene), polyoxyethylene content averages either 8, 9, or 40 moles.
- A pigment is a colored, black, white, or fluorescent particulate organic or inorganic solid. These solids are usually insoluble in, and essentially physically and chemically unaffected by, the vehicle or substrate into which it is incorporated. FDA-approved pigments includes iron oxides, titanium dioxide, extender pigments ultramarine pigments, manganese violet, mixed metal oxide pigments, fluorescent pigments, carbon black, magnetite, lodestone, magnetic iron oxide. Ultramarine pigments are insoluble inorganic compounds that are available in a wide range of blue shades, green shades, violets, and pink. Manganese violet is FDA approved for cosmetic applications. It has excellent lightfastness (8) and bleed resistance (5).
- Zinc oxide is recognized as a mild antimicrobial, wound healing and sunscreen agent. It primarily absorbs UVA light rather than scattering or reflecting, non-irritating, non-comedogenic, and micronized by forming many small micro particles for cosmetic use. Titanium dioxide is derived from Titanium, a highly reflective white chalky mineral, non-irritating, non-comedogenic, micronized by forming many small micro particles for cosmetic use, listed in the FDA monograph as one of the top and most effective active ingredients for sun protection. Titanium dioxide is the most important white pigment currently produced commercially. The pigment is used in a wide range of applications including inks, textiles, paper, paints, food, and pharmaceuticals. Pure titanium dioxide (TiO2) is stable, nonvolatile, and largely insoluble. Regular titanium dioxide is highly stable under most conditions. However, it has some photocatalytic activity (i.e. promotes reactions between other chemicals), especially in direct sunlight. Titanium dioxide nanoparticles appear to have much greater photocatalytic activity than regular titanium dioxide powder and might trigger formation of harmful free radicals when exposed to sunlight. Most manufacturers of titanium dioxide nanoparticles coat them to reduce or eliminate such effects.
- Titanium dioxide is a physical sunscreen protecting against UVB and short UVA (a.k.a. UNA-1) light. It has a long history of seemingly safe use and is not irritating. Its disadvantages include unsightly whitish tint and insufficient protection against long UVA (a.k.a. UVA-2). It may also help generate harmful free radicals via photocatalytic mechanism when exposed to sunlight. These effects may not have significant impact in topical use but the issue needs to be researched. Nanoparticle forms of titanium dioxide are less unsightly but their potential risks are unclear and may be greater than those associated with regular forms. More research is clearly needed. To increase protection and extend its range, titanium dioxide is usually combined with chemical UVB and UVA blockers and/or zinc oxide.
- The main complaint about titanium dioxide-based sunscreens is that they leave unsightly white residue. In fact, titanium dioxide creates stronger whitish tint than zinc oxide at comparable concentrations. This problem has been partly addressed by the advent of titanium dioxide nanoparticles as a sunscreen agent. Titanium dioxide nonoparticles have different optical properties and tend to produce much less whitish tint than regular powdered titanium dioxide. Yet, early research indicates that titanium dioxide nanoparticles retain the capacity to protect from UVB and short UVA (UVA-2) light. However, the safety of titanium dioxide nanoparticles remains a controversial subject. When exposed to sunlight (and possibly even other light), titanium dioxide nanoparticles may promote generation of free radicals and increase the risk of mutations—more so that regular titanium dioxide. Furthermore, in one UCLA study, titanium dioxide nanoparticles administered orally to mice in water were shown to cause genetic damage, such as mutations and DNA breaks. However, this effect may not be relevant to topical use as long as titanium dioxide nanoparticles do not penetrate stratum corneum (the outer skin layer consisting mostly of dead cells). Furthermore, manufacturers typically cover titanium dioxide nanoparticles with special coating, which increases the stability and reduces photoreactivity of the particles. Finally, there is a question whether titanium dioxide nanoparticles, could penetrate the skin, reach systemic circulation and accumulate in body organs. At present, there is no clear evidence that they do, but this is a valid concern that needs to be researched. Until then, it may be prudent to avoid the products with titanium dioxide nanoparticles (regular titanium dioxide should be ok).
- Titanium dioxide is in many ways similar to zinc dioxide as a sun blocking agent. However, zinc oxide has advantages of having broader range, anti-irritant properties and less opacity at comparable concentrations. In commercial sunscreens, titanium dioxide is usually combines with chemical UVB blockers. Sometimes it is also combined with other physical (zinc oxide) and/or chemical UVA blockers.
- Inflammation is the body's response to irritation or injury, and is characterized by redness, warmth, swelling, and pain. Anti-inflammatory refers to the property of a substance or treatment that reduces inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs), alleviate pain by counteracting the cyclooxygenase (COX) enzyme. On its own COX enzyme synthesizes prostaglandins, creating inflammation. In whole the NSAIDs prevent the prostaglandins from ever being synthesized, reducing or eliminating the pain. Some common examples of NSAIDs are: aspirin, ibuprofen, and naproxen. NSAIDs are used to treat a variety of conditions that cause inflammation. NSAIDs are also used to treat pain from injury or other causes of long-term pain. NSAID can reduce inflammation and relieve pain, and these drugs include ibuprofen, naproxen sodium, aspirin, ketoprofen, procaine, cocaine, lidocaine, priocaine, bupivacaine, levobupivacaine, ropivacaine, and dibucaine.
- Local anesthetics are agents that prevent transmission of nerve impulses without causing unconsciousness. They act by binding to fast sodium channels from within (in an open state). Local anesthetics can be either ester or amide based. Ester local anesthetics (e.g., procaine, amethocaine, cocaine) are generally unstable in solution and fast-acting, and allergic reactions are common. Amide local anesthetics (e.g., lidocaine, prilocalne, bupivicaine, levobupivacaine, ropivacaine, mepivacaine and dibucaine) are generally heat-stable, with a long shelf life (around 2 years). They have a slower onset and longer half-life than ester anaesthetics, and are usually racemic mixtures, with the exception of levobupivacaine (which is S(−)-bupivacaine) and ropivacaine (S(−)-ropivacaine). These agents are generally used within regional and epidural or spinal techniques, due to their longer duration of action, which provides adequate analgesia for surgery, labor, and symptomatic relief.
- Antihemorrhagic agents used in medicine have various mechanisms of action. Systemic drugs work by inhibiting fibrinolysis or promoting coagulation. Locally-acting hemostatic agents work by causing vasoconstriction or promoting platelet aggregation. There are several widely used hemostatic materials, including oxidized regenerated cellulose, gelatin, fibrin, thrombin, alginate, zeolite, collagen and chitosan. For example, microfibrillar collagen hemostat (MCH) is a topical agent composed of resorbable microfibrillar collagen. It attracts platelets and allows for the formation of a blood clot when it comes into contact with blood. Unlike the hemostatic clamp, no mechanical action is involved. The surgeon presses the MCH against a bleeding site, and the collagen attracts and helps with the clotting process to eventually stop bleeding. The practical application for MCH is different from that of the hemostatic clamp. It is not possible, for example, to stop a severed artery from gushing blood by using a patch of MCH and wait for the clotting process. The blood vessel must be mechanically clamped and repaired.
- The composition of any of the above embodiment can be provided in a gel, solid, or liquid form, can be prepared in a form that is pharmaceutically acceptable.
- In one embodiment, the present disclosure provides a composition prepared by admixing PVA and siloxane in a solvent, wherein the siloxane comprises a hydrophilic group. Examples of PVA, siloxane, solvent and hydrophilic group are provided above and generally in the disclosure.
- Also provided, in one embodiment, is a film that is obtained by reducing the content of the solvent in a composition of any of the above embodiments, or a film that is obtainable by reducing the content of the solvent in a composition of any of the above embodiments. In one aspect, the solvent is reduced by evaporation.
- Kits are also provided, comprising, in two or more separate compartments, polyvinyl acetal (PVA), siloxane and a solvent. In some aspects, the kit further comprises one or more of an antimicrobial agent, a pigment, an anti-inflammatory agent, an anesthetic agent or a hemostatic agent.
- The present disclosure also provides, in one embodiment, a method of preparing a film on a skin, comprising applying a suitable amount of a composition of any of the above embodiments on the skin and allowing the solvent to evaporate.
- Further provided is a method of preparing an antimicrobial sealant on a skin, comprising applying a suitable amount of a composition of the present disclosure on the skin and allowing the solvent to evaporate.
- Still provided, in one embodiment, is a method of preparing a body paint on a skin, comprising applying a suitable amount of a composition of the present disclosure on the skin and allowing the solvent to evaporate.
- It is also contemplated that any of above compositions or kits can be provided without the corresponding solvent. For the kits, the solvent can be provided in a separate compartment or package. In one aspect, the compositions or kits contain all the recited ingredients without a solvent. Before using the compositions or kits, the user can simply add a suitable amount of solvent to the composition or kit. Accordingly, relevant instructions can be provided, along with the compositions or kits.
- In another aspect, the solvent can be removed, or partially removed, from any of the compositions or kits, for the purpose of, e.g., storage or transportation. Removal of the solvent can be done with methods readily available in the art, as illustrated in Example 7, without allowing the composition to form a film during the process. For instance, freeze-drying (also known as lyophilisation, lyophilization or cryodesiccation) is a dehydration process typically used to preserve a perishable material or make the material more convenient for transport. Freeze-drying works by freezing the material and then reducing the surrounding pressure and adding enough heat to allow the frozen water in the material to sublime directly from the solid phase to the gas phase. The original compositions can be regenerated by adding proper amount of solvent to these solid, semi-solid, or gel-like, components following the same procedures described in the invention. This regeneration of composition will not adversely affect the performance.
- Likewise, methods of preparing and using the compositions or kits, without the solvent, are also provided.
- The present invention is further defined by reference to the following examples. It will be apparent to those skilled in the art that many modifications, both to threads and methods, may be practiced without departing from the scope of the current invention.
- This example provides a antimicrobial sealant that can be useful, for example, for minimizing surgical site infections.
- According to the CDC, each year in the US almost 500,000 surgical site infections (SSIs) occur, making them the second most-common healthcare-associated infection. In clean surgeries, direct inoculation of the patient's own skin flora is the primary source of incisional contamination. Because the skin cannot be completely sterilized and rebound growth of bacteria deep in the skin occurs during surgery. There are two ways to minimize SSI, maintaining a normal body temperature and using microbial sealants.
- In this example, 1.0 g of PVB (90000-120000 g/mol, Butvar® B 76 from Solutia, Inc.) was transferred to a flask (250 ml) filled with 200 proof ethanol (100 ml). The mixture was stirred for 5 hours to dissolve all PVB particles. Then 30 mg of (3-glycidoxypropyl) pentamethyldisiloxane was added to the solution above and the mixture was further stirred for 30 min.
- Using a brush, fingertip, or swab, a few droplets of the composition can be spread on a surface area of 4 inch2. Upon contact with the prepped skin, the film-forming composition above quickly forms a thin, flexible film which bonds to the skin surface, including skin contours, hair follicles and sweat glands. This breathable film immobilizes bacteria which survive the conventional surgical skin preparation and rebound during surgery, preventing migration or transference into the incision.
- This film has a unique mechanism of action which reduces skin Row contamination by physically immobilizing microorganisms—not by antimicrobial activity. Using the film-forming composition as microbial sealant does not contribute to antimicrobial resistance, therefore.
- In this example, 1.0 g of PVB (90000˜120000 g/mol, Butvar® B 76 from Solutia, Inc.) was transferred to a flask (250 ml) filled with methyl acetate (100 ml). The mixture was stirred for 5 hrs to dissolve all PVB particles. Then 30 mg of (3-glycidoxypropyl) pentamethyldisiloxane was added to the solution above and the mixture was further stirred for 30 min.
- In this example, 1.0 g of PVB (50000-80000 g/mol, Butvar® B 79 from Solutia, Inc.) was transferred to a flask (250 ml) filled with ethyl acetate (100 ml). The mixture was stirred for 5 hrs to dissolve all PVB particles. Then 30 mg of 1,3-bis(glycidoxypropyl)tetramethyldisiloxane, was added to the solution above and the mixture was further stirred for 30 min.
- In this example, 1.0 g of PVB (50000-80000 g/mol, Butvar® B 79 from Solutia, Inc.) was transferred to a flask (250 ml) filled with isopropyl acetate (100 ml). The mixture was stirred for 5 hrs to dissolve all PVB particles. Then 30 mg of epoxypropoxypropyl terminated polydimethylsiloxane was added to the solution above and the mixture was further stirred for 30 min.
- In this example, 1.0 g of PVB (50000-80000 g/mol, Butvar® B 79 from Solutia, Inc.) was transferred to a flask (250 ml) filled with butyl acetate (100 ml). The mixture was stirred for 5 hrs to dissolve all PVB particles. Then 30 mg of 1,3-bis(hydroxybutyl)tetramethyldisiloxane was added to the solution above and the mixture was further stirred for 30 min.
- Liquid bandage is a typical film forming composition, which is a topical skin treatment for minor cuts and sores that is sold by several companies. The products are mixtures of chemicals which create a polymeric layer which binds to the skin. This protects the wound by keeping dirt and germs out, and keeping moisture in. Compared to traditional bandages, liquid bandages are waterproof and germ-proof and can speed and enhance healing, and stay on for days. Liquid bandages can also be applied to some hard-to-reach areas, like the space between fingers.
- In this example, 30 g of PVB (50000-80000 g/mol, Butvar® B-79 from Solutia, Inc.) was transferred to a flask (250 ml) filled with 200 proof ethanol (100 ml). The mixture was stirred for 5 hrs to dissolve all PVB particles. Then 12 g of 3-(triethoxysilyl)propylsuccinic anhydride was added to the solution above and the mixture was further stirred for 30 min.
- Then either or both of the following ingredients were added: enzethonium chloride (0.2%) and lidocaine HCl (2.5%), to the mixture. Thus, a liquid bandage with antiseptic and anesthetic effect was formulated.
- In this example, 30 g of PVB (40000-70000 g/mol, Butvar® B-98 from Solutia, Inc.) was transferred to a flask (250 ml) filled with 200 proof ethanol (100 ml). The mixture was stirred for 5 hrs to dissolve all PVB particles. Then 12 g of mono-(2,3-epoxy)propylether terminated polydimethylsiloxane (Mw˜1000 g/mol), was added to the solution above and the mixture was further stirred for 30 min.
- To the composition above 2.0 wt % red pigment (Derma #17AA) was added. The formulation was then shaken well to form a stable dispersion. A water-repellent, breathable, non-tacky body paint was then fabricated with long-lasting time on skin.
- In this example, 10 g of PVB (120000-150000 g/mol, Butvar® B-74 from Solutia, Inc.) was transferred to a flask (250 ml) filled with 200 proof ethanol (100 ml). The mixture was stirred for 5 hrs to dissolve all PVB particles. Then 2 g of 1,3-bis(hydroxypropyl)tetramethyldisiloxane was added to the solution above and the mixture was further stirred for 30 min.
- When zinc oxide (10 wt %) and titanium oxide (10 wt %) particles were added to the formulation, a sun block with broad spectrum of blockade was made. The sun block stayed on skin for extended period and was not abraded off easily.
- A makeup sealer is a water-resistant, anti-perspiring coating on a completed makeup. When a perfume (Calone or methylbenzodioxepinone, trade-named Calone 1951 from Pfizer Inc.) (0.05%) is added to the composition , a makeup sealer is created and can be sprayed to the final makeup to form a flexible, water-repellent film to bind the makeup onto skin even in a hot summer day or on heavily perspiring skins.
- In this example, 2 g of PVB (170000-250000 g/mol, Butvar® B-72 from Solutia, Inc.) was transferred to a flask (250 ml) filled with 200 proof ethanol (100 ml). The mixture was stirred for 5 hrs to dissolve all PVB particles. Then 0.6 g of 3-[hydroxy(polyethyleneoxy)propyl]heptamethyltrisiloxane was added to the solution above and the mixture was further stirred for 30 min.
- In this example, 2 g of PVB (170000-250000 g/mol, Butvar® B-72 from Solutia, Inc.) was transferred to a flask (250 ml) filled with 200 proof ethanol (100 ml). The mixture was stirred for 5 hrs to dissolve all PVB particles. Then 0.4 g of 1,3-bis(3-carboxypropyl)tetramethyldisiloxane was added to the solution above and the mixture was further stirred for 30 min.
- When a biocide (benzethonium chloride, 0.85 wt %) was included in the formulations, anti-microbial coatings were readily available. Titanium oxide nano particles can disinfect or clean surfaces exposed to light, thus working as a bactericidal or photooxidizing agent. This formulation can clean soiling, control or suppress bacterial proliferation, and reduce the frequency of cleaning or disinfection in the food industry, kitchens, bathrooms, washrooms, hospitals, glazing and facades.
- In this example, 2 g of PVB (170000-250000 g/mol, Butvar® B-72 from Solutia, Inc.) can be grounded with a Spex Freezer/mill 6770 in liquid nitrogen for 10 cycles at default configuration by the manufacturer, each cycle lasting 3 minutes. Particles of about 5 μm˜about 100 μm are generated. To these particles, a solution of 1,3-bis(hydroxypropyl)tetramethyldisiloxane (0.4 g) in chloroform (2 ml) is introduced and mixed manually with a spatula for 2 minutes to create uniformly coated particles. Finally, the coated particles are dried under vacuum at ambient temperature for 4 hrs for use later.
- The disclosure illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms “comprising”, “including,” containing”, etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the disclosure claimed.
- Thus, it should be understood that although the present disclosure has been specifically disclosed by preferred embodiments and optional features, modification, improvement and variation of the disclosure embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications, improvements and variations are considered to be within the scope of this disclosure. The materials, methods, and examples provided here are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the disclosure.
- The disclosure has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the disclosure. This includes the generic description of the disclosure with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
- In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.
- All publications, patent applications, patents, and other references mentioned herein are expressly incorporated by reference in their entirety, to the same extent as if each were incorporated by reference individually. In case of conflict, the present specification, including definitions, will control.
Claims (1)
1. A composition comprising polyvinyl acetal (PVA) and siloxane, wherein the siloxane comprises a hydrophilic group.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/332,391 US20140328776A1 (en) | 2010-05-11 | 2014-07-16 | Film forming personal care compositions and methods |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33375010P | 2010-05-11 | 2010-05-11 | |
PCT/US2011/035785 WO2011143131A1 (en) | 2010-05-11 | 2011-05-09 | Film forming personal care compositions and methods |
US201213696726A | 2012-11-07 | 2012-11-07 | |
US14/332,391 US20140328776A1 (en) | 2010-05-11 | 2014-07-16 | Film forming personal care compositions and methods |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/035785 Continuation WO2011143131A1 (en) | 2010-05-11 | 2011-05-09 | Film forming personal care compositions and methods |
US13/696,726 Continuation US8808732B2 (en) | 2010-05-11 | 2011-05-09 | Film forming personal care compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140328776A1 true US20140328776A1 (en) | 2014-11-06 |
Family
ID=44914661
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/696,726 Expired - Fee Related US8808732B2 (en) | 2010-05-11 | 2011-05-09 | Film forming personal care compositions and methods |
US14/332,391 Abandoned US20140328776A1 (en) | 2010-05-11 | 2014-07-16 | Film forming personal care compositions and methods |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/696,726 Expired - Fee Related US8808732B2 (en) | 2010-05-11 | 2011-05-09 | Film forming personal care compositions and methods |
Country Status (3)
Country | Link |
---|---|
US (2) | US8808732B2 (en) |
CN (1) | CN103025784A (en) |
WO (1) | WO2011143131A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110143588A (en) * | 2019-04-18 | 2019-08-20 | 浙江大学 | A method of transferring graphene based on liquid band-aid protective layer |
CN112533583A (en) * | 2018-08-09 | 2021-03-19 | 花王株式会社 | Method for producing coating film |
US11253439B2 (en) | 2017-04-18 | 2022-02-22 | Kao Corporation | Method for producing cosmetic coating |
EP3833317A4 (en) * | 2018-08-09 | 2022-05-04 | Kao Corporation | PROCESS FOR MANUFACTURING MULTICOLOR COATINGS |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103157126B (en) * | 2012-03-26 | 2014-11-12 | 何星剑 | Woundplast glue and preparing method thereof |
CN102631305B (en) * | 2012-05-11 | 2013-04-10 | 苏州宜生生物技术有限公司 | Finishing liquid |
US9078947B2 (en) | 2013-03-15 | 2015-07-14 | Kimberly-Clark Worldwide, Inc. | Composition for forming a porous absorbent structure |
US20140271762A1 (en) | 2013-03-15 | 2014-09-18 | Ecolab Usa Inc. | Non-Sorptive or Minimally Sorptive Disinfectant Wipes |
CN105979933A (en) * | 2013-11-06 | 2016-09-28 | 因凡瑞斯有限公司 | Pharmaceutical preparations, methods of production and uses thereof |
US20150343112A1 (en) * | 2014-06-02 | 2015-12-03 | Problem Solving Products, Llc | Liquid bandage |
KR20170134572A (en) | 2015-04-06 | 2017-12-06 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | Removable film forming gel composition and method of application thereof |
US20160295859A1 (en) | 2015-04-09 | 2016-10-13 | Ecolab Usa Inc. | Disposable antimicrobial wipes and methods of making |
JP6203363B2 (en) * | 2015-10-19 | 2017-09-27 | 花王株式会社 | Method for producing coating film |
SG11201803180PA (en) * | 2015-10-19 | 2018-05-30 | Kao Corp | Method for producing coating film |
PL3402575T4 (en) * | 2016-01-15 | 2021-07-19 | Salon Commodities, Inc. | Methods and compositions for treating damaged hair |
US10639390B2 (en) * | 2016-02-25 | 2020-05-05 | Ralph Birchard Lloyd | System and method for disinfecting an occupied environment using direction controlled germicidal radiation |
FR3048609B1 (en) * | 2016-03-08 | 2019-06-14 | Fiabila Sas | COMPOSITIONS FOR NAIL POLISH |
US11471481B2 (en) * | 2016-06-29 | 2022-10-18 | Iview Therapeutics, Inc. | Rapid-deposition thin-film forming compositions as effective wound care treatment |
US20190350825A1 (en) * | 2016-11-22 | 2019-11-21 | Kao Corporation | Method for producing coating film for cosmetic preparation |
RU2639379C1 (en) * | 2016-11-28 | 2017-12-21 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр гематологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ гематологии" Минздрава России) | Hemostatic coating in form of sponge or film (versions) |
BR112019013464A2 (en) * | 2016-12-28 | 2020-01-07 | Kao Corporation | METHOD FOR MANUFACTURING A COATING FILM |
US10413505B1 (en) | 2017-02-07 | 2019-09-17 | Genus Lifesciences Inc. | Pharmaceutical compositions and methods of using the same |
US10149843B1 (en) | 2017-02-07 | 2018-12-11 | Gneus Lifescineces Inc. | Pharmaceutical compositions and methods of using the same |
US10231961B1 (en) | 2017-02-07 | 2019-03-19 | Genus Lifesciences Inc. | Pharmaceutical compositions and methods of using the same |
CA3057825A1 (en) | 2017-03-25 | 2018-10-04 | Salon Commodities, Inc. | Methods and compositions for straightening hair |
US20200155423A1 (en) * | 2017-04-18 | 2020-05-21 | Kao Corporation | Method for producing coating |
SG11201909370WA (en) * | 2017-04-19 | 2019-11-28 | Kao Corp | Composition for forming coating |
CA3089352A1 (en) | 2018-01-29 | 2019-08-01 | Pathelen Health Care Ag | Hydrophilic/hydrophobic pharmaceutical composition and method of its production and use |
KR102202389B1 (en) | 2018-03-09 | 2021-01-12 | 주식회사 엘지생활건강 | Formulation to form film on skin |
WO2020210889A1 (en) * | 2019-04-18 | 2020-10-22 | Hexsel, Doris Maria | Dye composition for marking organic tissue with anaesthetic and method for applying same |
CN114854217B (en) * | 2022-06-16 | 2023-05-09 | 陕西科技大学 | A biodegradable water-repellent and anti-ultraviolet gelatin-based bioplastic film and its preparation method |
WO2023247794A1 (en) * | 2022-06-24 | 2023-12-28 | Nouryon Chemicals International B.V. | Polyvinyl alcohol film-forming polymers for alcohol-based sunscreen formulations and methods of using same |
CN116440318A (en) * | 2023-04-25 | 2023-07-18 | 湖南省天香生物科技有限责任公司 | Liquid band-aid capable of stopping bleeding rapidly and preparation method thereof |
CN119039908B (en) * | 2024-09-23 | 2025-03-18 | 东莞市博翔电子材料有限公司 | A high-viscosity acrylic adhesive for new energy vehicles |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5789461A (en) * | 1994-09-06 | 1998-08-04 | Ciba Vision Corporation | Methods of forming an extended wear ophthalmic lens having a hydrophilic surface |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2506320A (en) * | 1945-12-06 | 1950-05-02 | Anaconda Wire & Cable Co | Method of preparing solutions of mixtures of siloxane resin and polyvinyl acetal resin, wherein cresylic acid is used as one of the solvents |
DE10140131B4 (en) * | 2001-08-16 | 2007-05-24 | Wacker Polymer Systems Gmbh & Co. Kg | Silane-modified polyvinyl acetals |
US20100233146A1 (en) * | 2002-09-09 | 2010-09-16 | Reactive Surfaces, Ltd. | Coatings and Surface Treatments Having Active Enzymes and Peptides |
EP1462116A1 (en) * | 2003-03-29 | 2004-09-29 | Villitech SARL | Composition for treating the gastrointestinal tract |
DE10338479A1 (en) * | 2003-08-21 | 2005-04-14 | Wacker Polymer Systems Gmbh & Co. Kg | Silicone-containing polyvinyl acetals |
US20050268405A1 (en) | 2004-05-28 | 2005-12-08 | Gaelle Brun | Composition for dyeing keratin fibers, comprising at least one pigment and polymers capable of reacting with each other to form covalent bonds |
US20060110415A1 (en) * | 2004-11-22 | 2006-05-25 | Bioderm Research | Topical Delivery System for Cosmetic and Pharmaceutical Agents |
-
2011
- 2011-05-09 US US13/696,726 patent/US8808732B2/en not_active Expired - Fee Related
- 2011-05-09 WO PCT/US2011/035785 patent/WO2011143131A1/en active Application Filing
- 2011-05-09 CN CN2011800221494A patent/CN103025784A/en active Pending
-
2014
- 2014-07-16 US US14/332,391 patent/US20140328776A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5789461A (en) * | 1994-09-06 | 1998-08-04 | Ciba Vision Corporation | Methods of forming an extended wear ophthalmic lens having a hydrophilic surface |
US5789461B1 (en) * | 1994-09-06 | 2000-11-21 | Ciba Vision Corp | Methods of forming an extended wear ophthalmic lens having a hydrophilic surface |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11253439B2 (en) | 2017-04-18 | 2022-02-22 | Kao Corporation | Method for producing cosmetic coating |
CN112533583A (en) * | 2018-08-09 | 2021-03-19 | 花王株式会社 | Method for producing coating film |
EP3833317A4 (en) * | 2018-08-09 | 2022-05-04 | Kao Corporation | PROCESS FOR MANUFACTURING MULTICOLOR COATINGS |
EP3834808A4 (en) * | 2018-08-09 | 2022-05-18 | Kao Corporation | PROCESS FOR MAKING A COATING FILM |
US11338308B2 (en) | 2018-08-09 | 2022-05-24 | Kao Corporation | Method for producing wearable coating |
US11759803B2 (en) | 2018-08-09 | 2023-09-19 | Kao Corporation | Method for producing wearable coating |
US12226497B2 (en) | 2018-08-09 | 2025-02-18 | Kao Corporation | Method for producing coating film |
CN110143588A (en) * | 2019-04-18 | 2019-08-20 | 浙江大学 | A method of transferring graphene based on liquid band-aid protective layer |
Also Published As
Publication number | Publication date |
---|---|
WO2011143131A1 (en) | 2011-11-17 |
US8808732B2 (en) | 2014-08-19 |
CN103025784A (en) | 2013-04-03 |
US20130058880A1 (en) | 2013-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8808732B2 (en) | Film forming personal care compositions and methods | |
JP7054212B2 (en) | A novel fast-adhesive thin-film forming composition as an effective wound care procedure | |
US10143755B2 (en) | Anhydrous hydrogel composition and delivery system | |
AU2012319004B2 (en) | Sacrificial adhesive coatings | |
US6214332B1 (en) | Methods for closing suturable wounds by use of cyanoacrylate ester compositions comprising an antimicrobial agent | |
EP1809264B1 (en) | Antimicrobial amorphous compositions | |
US8821910B2 (en) | Alkylaminoalkyl oligomers as broad-spectrum antimicrobial agent | |
KR20120104156A (en) | Particles incorporating antimicrobial agents | |
CA2002404A1 (en) | Delivery system for pharmaceutical or therapeutic actives | |
JP2008535956A (en) | Liquid coating composition | |
WO2000072850A1 (en) | Foot care compositions containing quaternary ammonium organosilanes | |
US20180280431A1 (en) | Process for Obtaining the Product for Prevention, Interruption of Dental Caries Lesions and Teeth Remineralization and Obtained Product | |
WO2019040376A1 (en) | Polymeric topical antiseptic compound and method of use | |
US20250127802A1 (en) | Halide-free ammonium silanes | |
US20050042196A1 (en) | Antimicrobial phenol containing cyanoacrylate compositions | |
WO1999023150A1 (en) | Cyanoacrylate polymer compositions comprising an antimicrobial agent | |
WO2001003656A1 (en) | Antimicrobial artificial nail composition and methods for preparing and using same | |
US20080152614A1 (en) | Method and kit for skin lesion prevention and/or protection | |
JPH03206009A (en) | Antimicrobial agent, antimicrobial resin composition, molded product of antimicrobial resin, antimicrobial water tank made of synthetic resin, antimicrobial synthetic fiber, paper having antimicrobial property, antimicrobial coating, local antimicrobial agent and cosmetic | |
WO2019028050A1 (en) | Alkyl dimethyl organosilane quaternaries in persistent systems and methods | |
JP2010005161A (en) | Antifungal film-forming agent for epidermis | |
AU4911297A (en) | Methods for treating non-suturable, superficial wounds by use of cyanoacrylat e ester compositions comprising an antimicrobial agent | |
KR20250125848A (en) | Polyphenol-polymer coacervate cosmetic adhesive composition | |
BR112018012176B1 (en) | composite material, non-therapeutic use, composition and preparation process of a composite material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |